

1 **Increased circulating fibronectin, depletion of natural IgM and heightened EBV, HSV-1**
2 **reactivation in ME/CFS and long COVID**

3

4

5 Zheng Liu¹, Claudia Hollmann¹, Sharada Kalanidhi², Arnhild Grothey¹, Sam Keating¹, Irene
6 Mena-Palomo¹⁴, Stephanie Lamer³, Andreas Schlosser³, Agnes Kaiping¹, Carsten Scheller¹,
7 Franzeska Sotzny⁴, Anna Horn⁵, Carolin Nürnberger⁵, Vladimir Cejka⁶, Boshra Afshar¹,
8 Thomas Bahmer⁷, Stefan Schreiber⁷, Jörg Janne Vehreschild⁸, Olga Miljukov⁵, Christian
9 Schäfer⁹, Luzie Kretzler¹⁰, Thomas Keil¹⁰, Jens-Peter Reese⁵, Felizitas A Eichner⁵, Lena
10 Schmidbauer⁵, Peter U Heuschmann^{5,14,15}, Stefan Störk⁶, Caroline Morbach⁶, Gabriela
11 Riemekasten¹¹, Niklas Beyersdorf¹, Carmen Scheibenbogen⁴, Robert K Naviaux¹², Marshall
12 Williams¹³, Maria E Ariza^{13#}, Bhupesh K Prusty^{1#}

13

14

15 ¹Institute for Virology and Immunobiology, Julius-Maximilians-University of Würzburg,
16 Würzburg, Germany

17 ²Stanford Genome Technology Center, Stanford University School of Medicine, Stanford, CA,
18 USA

19 ³Rudolf Virchow Center, Center for Translational Bioimaging, Julius-Maximilians-University of
20 Würzburg, Germany

21 ⁴Institute for Medical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany

22 ⁵Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-University of Würzburg,
23 Würzburg, Germany.

24 ⁶Department of Clinical Research & Epidemiology, Comprehensive Heart Failure Center and
25 Department of Medicine I, University Hospital Würzburg, Würzburg, Germany

26 ⁷Internal Medicine Department I, University Hospital Schleswig-Holstein UKSH - Campus Kiel,
27 Kiel, Germany

28 ⁸University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of
29 Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf,
30 Germany

31 ⁹University Medicine Greifswald, Institute of Clinical Chemistry and Laboratory Medicine,
32 Greifswald, Germany

33 ¹⁰Charité - Universitätsmedizin Berlin and Berlin Institute of Health (BIH), Berlin, Germany

34 ¹¹Klinik für Rheumatologie, Universitätsklinikum Schleswig-Holstein, Lübeck

35 ¹²Departments of Medicine, Pediatrics, and Pathology, University of California, San Diego

36 School of Medicine, San Diego, USA

37 ¹³Institute for Behavioral Medicine Research (IBMR), The Ohio State University, Columbus,

38 Ohio, USA

39 ¹⁴Institute for Medical Data Sciences, University Hospital Würzburg, Würzburg

40 ¹⁵Clinical Trial Center, University Hospital Würzburg, Würzburg

41

42

43

44

45

46

47 # Co-senior authors

48 Please send correspondence to: bhupesh.prusty@uni-wuerzburg.de;

49 maria.ariza@osumc.edu

50

51

52 Key words: ME/CFS, long COVID, (n)IgM, Fibronectin, EBV, HSV-1, HHV-6, dUTPase

53

54

55

56 **Summary**

57 Myalgic Encephalomyelitis/ Chronic Fatigue syndrome (ME/CFS) is a complex, debilitating,
58 long-term illness without a diagnostic biomarker. ME/CFS patients share overlapping
59 symptoms with long COVID patients, an observation which has strengthened the infectious
60 origin hypothesis of ME/CFS. However, the exact sequence of events leading to disease
61 development is largely unknown for both clinical conditions. Here we show antibody
62 response to herpesvirus dUTPases, particularly to that of Epstein-Barr virus (EBV) and HSV-1,
63 increased circulating fibronectin (FN1) levels in serum and depletion of natural IgM against
64 fibronectin ((n)IgM-FN1) are common factors for both severe ME/CFS and long COVID. We
65 provide evidence for herpesvirus dUTPases-mediated alterations in host cell cytoskeleton,
66 mitochondrial dysfunction and OXPHOS. Our data show altered active immune complexes,
67 immunoglobulin-mediated mitochondrial fragmentation as well as adaptive IgM production
68 in ME/CFS patients. Our findings provide mechanistic insight into both ME/CFS and long
69 COVID development. Finding of increased circulating FN1 and depletion of (n)IgM-FN1 as a
70 biomarker for the severity of both ME/CFS and long COVID has an immediate implication in
71 diagnostics and development of treatment modalities.

72

73

74 **Main Text**

75 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is considered as a chronic
76 post viral illness that shares several overlapping clinical symptoms with long COVID or post-
77 acute sequelae of SARS-CoV-2 infection (PASC)¹ including neurological disturbances, extreme
78 fatigue, post-exertional malaise (PEM), and postural orthostatic tachycardia syndrome
79 (POTS). Immune dysregulation, microbiota dysbiosis, autoimmunity, vascular dysfunction,
80 dysfunctional neurological signaling are some of the key hypothesized mechanisms for both
81 the diseases¹. However, there are no diagnostic biomarkers for the disease diagnosis and no
82 treatment modalities yet. The infectious origin hypothesis of ME/CFS is long postulated and
83 is supported by development of long COVID after SARS-CoV-2 infection. Our laboratories
84 have postulated the idea of herpesvirus reactivation as a key mechanism of both ME/CFS as
85 well as long COVID development, which is now corroborated by several groups^{2,3}. In this
86 paper, we provide evidence for frequent HSV-1 and EBV reactivation in both ME/CFS and
87 long COVID patients and provide an experimental reasoning for potential cellular damage
88 through herpesvirus dUTPase proteins. Furthermore, we show that ME/CFS patients have
89 altered autoimmune features, which possibly developed because of depletion of natural IgM
90 ((n)IgM) within primary hematopoietic organs. Our study further focuses on fibronectin
91 protein that shows altered expression and immune response patterns that correlates with
92 disease severity.

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107 **Results**

108 ***Increased HSV-1 and EBV reactivation in ME/CFS and long COVID***

109 Reactivation of different herpesviruses including HHV-6, HHV-7 and EBV is frequently
110 associated with ME/CFS development^{4,5}. Most recently, reactivation of several herpesviruses
111 including EBV was detected during acute SARS-CoV-2 infection². To test the possibility that
112 these dormant viruses are being reactivated in long COVID patients and are producing
113 dUTPases, we examined the humoral response against the viral dUTPases of EBV, HHV-6 and
114 HSV-1 in a cohort of patients (n=278) at least after 6 months of first SARS-CoV-2 infection
115 (COVIDOM cohort⁶). Only 6% of the patients of this cohort were hospitalized during the
116 acute SARS-CoV-2 infection while rest of the 94% of the patients had mild to moderate
117 SARS-CoV-2 infection without the need for hospitalization⁷. This patient cohort was further
118 divided into three groups based on a scoring system⁶, which separated mild and severe long
119 COVID patients (mild (n=107) and severe LC (n=22) respectively) from those who did not
120 show any major health issues post SARS-CoV-2 infection and recovery (No LC, n=149).
121 Distribution of these patient and control groups according to their age and gender is shown
122 in Extended Fig. 1a (Supplementary Table 1). The long COVID cohort were compared to
123 healthy blood donors (HC, n=31) and ME/CFS patients (ME/CFS, n=77). As commercial
124 dUTPase ELISA based assay is not available, we used purified recombinant dUTPase proteins
125 as a bait to capture human IgG in Western blots (Fig. 1a). Our results showed heightened IgG
126 responses against EBV and HSV-1 dUTPases in ME/CFS and long COVID patients (Fig. 1b,
127 Extended Fig. 1b). Strikingly higher IgG response to HSV-1 dUTPase was detected in mild and
128 severe long COVID patients (Fig. 1b). A modest but significant increase in IgG response
129 against HHV-6 dUTPase was observed in ME/CFS patients (Fig. 1b, Extended Fig. 1) but not in
130 the cohorts of SARS-CoV-2 infected patients, which had decreased IgG response against
131 HHV-6 dUTPase in comparison to healthy controls. These results suggest an overall increase
132 in EBV and HSV-1 reactivation in both ME/CFS and SARS-CoV-2 infected patients.

133

134 ***Herpesvirus dUTPase proteins alters mitochondrial architecture***

135 The increased anti-dUTPase IgG response observed in patient cohorts after 6 months of first
136 SARS-CoV-2 infection suggests EBV and HSV-1 reactivation potentially contributing to

137 disease development. Studies by our group have shown that the herpesviruses dUTPases
138 represent a new family of Pathogen Associated Molecular Patterns (PAMPs)⁷ protein ligands
139 with novel immune and neuromodulatory properties, independent of the enzymatic activity.
140 Hence, we further explored the potential role of these viral proteins in human biology.
141 Transient expression of HSV-1, HHV-6 and EBV dUTPase in cultured human cells induced a
142 hyperpolarized and hyperfused mitochondrial phenotype (Fig. 1c, Extended Fig. 2a) with
143 increased mitochondrial surface area (Fig. 1d, Extended Fig. 2b). The appearance was similar
144 to the stress-induced mitochondrial hyperfusion (SIMH) phenotype that is seen with
145 exposure to certain environmental chemicals⁸, nutrient depletion, viral infections, and in
146 certain chronic disease states⁹. In U2-OS cells, all the three dUTPases were predominantly
147 localized within the nucleus (Extended Fig. 2a). In HEK293 cells, only EBV dUTPase localized
148 to the nucleus whereas HSV-1 and HHV-6 dUTPases remained mostly within cytoplasm (Fig.
149 1c). EBV dUTPase (BLLF3) is known to be localized within nucleus¹⁰ whereas HSV-1 dUTPase
150 (UL50) is reported to be localized within both cytoplasm and nucleus. Irrespective of the
151 protein localization, mitochondrial fusion protein Mfn1 was upregulated by all the three viral
152 dUTPases (Fig. 1e). Other mitochondrial fusion proteins like Mfn2, Miga1, remained
153 unchanged (Extended Fig. 2c). Mitophagy was inhibited to various degree by all the three
154 dUTPases, EBV dUTPase being the most efficient in decreasing LC3 β protein expression (Fig.
155 1e). Tetramethylrhodamine ethyl ester (TMRE) staining of dUTPase transfected cells in the
156 presence of ATP synthase inhibitor, oligomycin showed a decrease in mitochondrial
157 membrane potential in cells expressing EBV dUTPase (Fig. 1f) suggesting poor mitochondrial
158 health and energetics particularly in presence of EBV dUTPase. HSV-1 and HHV-6 dUTPase
159 did not show any significant effect (Extended Fig. 2d). EBV dUTPase expressing cells showed
160 characteristics of hyperpolarized mitochondria with higher mitochondrial membrane
161 potential in comparison to mock vector transfected cells in the absence of oligomycin
162 (Extended Fig. 2e). On the other hand, exposing U2-OS cells in culture to recombinant EBV
163 dUTPase induced Drp-1 dependent mitochondrial fragmentation and appearance of
164 spherical hyperpolarized mitochondria (Extended Fig. 2f-g) in a dose dependent manner that
165 showed increased mitochondrial membrane potential under normal growth conditions,
166 which decreased in presence of oligomycin suggesting poor mitochondrial health (Extended
167 Fig. 2h). Such spherical mitochondrial phenotype was previously described as 'mitosphere'
168 that induces oxidative stress¹¹. We constitutively expressed all the three viral dUTPases and

169 immunoprecipitated viral dUTPase proteins in HEK293 cells (Extended Fig. 2i). Mass
170 spectrometry analysis of co-immunoprecipitated proteins showed enrichment of several
171 cellular cytoskeleton associated proteins including neurofilament medium chain (NEFM),
172 epiplakin 1 (EPPK1), plectin (PLEC) (Fig. 1g-h, Extended Fig. 2j-k) suggesting strong
173 association of host cell cytoskeleton with herpesvirus dUTPases. Cellular localization of
174 dUTPase proteins seems to be not associated with its interaction with cell cytoskeleton as
175 both HSV-1 dUTPase and EBV dUTPase showed similar interacting partners. We further
176 validated some of the interacting partners of EBV and HSV-1 dUTPases identified by mass
177 spectrometry through immunoblotting (Fig. 1h, Extended Fig. 2l). These results suggest that
178 herpesvirus dUTPases interact with host cell cytoskeleton and alter mitochondrial
179 architecture as well as function.

180

181 ***Immunoglobulins and mitochondrial fragmentation in ME/CFS***

182 Chronic, recurrent HSV-1 and EBV infections lead to development of autoimmunity^{12,13}. We
183 hypothesized that autoimmunity-induced antibodies in serum might induce mitochondrial
184 dysfunction as shown by others^{14,15}. To check if immunoglobulins (Igs) isolated from ME/CFS
185 patients can induce mitochondrial alterations *in vitro*, we purified Ig fractions from ME/CFS
186 patients (n=17) and healthy controls (n=13) using Sepharose G columns. Exposure of as low
187 as 1 µg of purified immunoglobulins from severe ME/CFS patients fragmented mitochondria
188 within 12 h of exposure (Fig. 2a-b). The mitochondrial fragmentation phenotype for severe
189 ME/CFS patients was cell-type dependent and was pronounced in primary human umbilical
190 vein endothelial cells (HUVEC) (Fig. 2a-b). Ig from healthy controls showed a mixed effect on
191 mitochondrial architecture whereas Ig from mild/moderate ME/CFS patients had a modest
192 but significant effect on mitochondria in HUVEC cells. Fragmented mitochondrial phenotype
193 by Ig from severe ME/CFS patients showed decreased Mfn1 and PLD6 protein levels (Fig. 2c).
194 Efficiency of IgG purification was tested by analyzing antibodies against EBV dUTPase in EBV
195 positive and negative patient serum, which showed enriched EBV dUTPase antibodies after
196 purification (Extended Fig. 3a, b).

197 Purified IgG from human serum mostly contains immunoglobulin fractions with freely
198 available Fc receptors along with associated immune complex proteins. These immune
199 complex proteins can also potentially be a factor that can induce mitochondrial
200 fragmentation. Hence, we analyzed the same purified IgG fractions from healthy control

201 (n=12) and ME/CFS patients (n=15), that were used in mitochondrial studies, by mass
202 spectrometry. IgG and IgM bound immune complex purification was of high quality and
203 uniform throughout the samples as validated by similar enrichment of complement
204 components in all the samples (Extended Fig. 3c). Only three cellular proteins showed
205 decreased amounts within the immune complex of ME/CFS patient groups in comparison to
206 healthy controls (Fig. 2d, Extended Fig. 3d), i.e, fibronectin (FN1), alpha2 macroglobulin
207 (A2M) and serotransferrin (TF).

208 In an independent microarray study, we also detected IgM against fibronectin antigen as one
209 of the few IgMs that were selectively decreased in severe ME/CFS patients. To test potential
210 IgM response against selective autoantigens frequently involved in autoimmune diseases,
211 IgM levels were tested against 120 autoantigens (Supplementary Table 2) in a small cohort
212 of mild to severe ME/CFS patients (n=12) and healthy controls (n=3). Samples were blinded
213 throughout the experimental procedure and data analysis. Multivariate clustering of log-
214 transformed data resulted in the observation that patients could be separated into distinct
215 groups comprising healthy, mild/moderate and severe patients (Fig. 2e) on the basis of IgM
216 antibody levels against autoantigens like PCNA, collagen V and VI, complement C3, CRP etc.
217 (Fig. 2f, Extended Fig. 4a-b). IgM against fibronectin was one of the 10 variables that
218 contributed to these clustering. These results suggest that decreased immunoglobulin
219 against fibronectin and other proteins are key features of severe ME/CFS.

220

221 ***ME/CFS and long COVID patients show increased amounts of circulating fibronectin***

222 FN1 interacts with circulating immune complex and aggregates with IgG, IgM and IgA
223 thereby playing a significant role in both the clearance of activated immune complexes and
224 tissue deposition of fibronectin-containing immune complexes in several diseases¹⁶. Lack of
225 fibronectin within immune complexes and their potential accumulation within blood can
226 indicate lack of protection against certain pathogenic infections. To check if overall
227 fibronectin protein expression is downregulated in ME/CFS or is specifically removed from
228 immune complexes for some reason, we measured circulating fibronectin levels in serum of
229 ME/CFS (n=66) patients and healthy controls (n=63). Circulating fibronectin levels were
230 significantly higher in ME/CFS patients in comparison to healthy controls as shown in the
231 Kernel Density plot (Fig. 2g-h). Serum FN1 levels showed a positive correlation with ME/CFS
232 severity as patients with bell scores of 0-20 had significantly higher FN1 levels (Fig. 2i, HC vs

233 Bell 0-20, ****P < 0.0001. Bell 0-20 vs Bell 30-50, **P = 0.0032) in serum than those with
234 bell score between 30-50 (Area under the receiver operator characteristic (AUROC) = 79.8%
235 for severe ME/CFS (Fig. 2j), P<0.0001). We further compared circulating fibronectin levels
236 within SARS-CoV-2 positive cohorts. Only long COVID patients (both mild and severe)
237 showed significantly higher circulating fibronectin levels (Fig. 2k, HC vs mild LC, **P =
238 0.0032. HC vs severe LC, *P = 0.0488) in comparison to healthy controls and SARS-CoV-2
239 positive but without long COVID individuals (No LC). Circulating fibronectin contains the
240 majority of plasma fibronectin (pFN1) secreted by hepatocytes and a minor fraction of
241 cellular fibronectin (cFN1) secreted by other cell types. We compared circulating FN1
242 composition between some of the ME/CFS patients to that of healthy controls, which
243 showed an overall increase in both extra domain A (EDA) negative pFN1 as well as EDA
244 domain and cell binding domain (CBD) positive cFN1 in ME/CFS patients (Extended Fig. 5a)
245 suggesting an overall increase in circulating fibronectin levels. Total human IgG was used as
246 loading control. Interestingly, we observed significant differences in circulating fibronectin
247 levels between male and females (Extended Fig. 5b). Particularly, healthy controls and SARS-
248 CoV-2 positive but no long COVID (no LC) groups showed significantly higher FN1 levels in
249 females than males (Extended Fig. 5b, HC male vs female, **P = 0.0014; No LC male vs
250 female, *P = 0.0204; severe LC male vs female, *P = 0.0347). Similarly, increasing FN1 levels
251 among female long COVID patients showed positive correlation with disease severity
252 (Extended Fig. 5c, HC male vs ME/CFS male, ****P = 0.0001; HC male vs mild LC male, *P =
253 0.012; HC female vs no LC female, *P = 0.0193; HC female vs mild LC female, ****P = 0.0006;
254 HC female vs severe LC female, **P = 0.0016), which was less among male long COVID
255 patients. However, because of the comparatively low levels of circulating FN1 among healthy
256 males, male ME/CFS patients showed a significant increase in FN1 levels (Extended Fig. 5c).
257 In summary, our results show increased circulating FN1 levels in ME/CFS and long COVID
258 patients that correlates with disease severity.

259

260 ***Depletion of IgM against FN1 correlates with disease severity***

261 One of the interesting observations from our antibody microarray studies was the decrease
262 in IgM antibodies against FN1 among some of the severe ME/CFS patients (Fig. 2a, Extended
263 Fig. 5d). Antibodies (IgG, IgM and IgA) against FN1 are frequently detected in plasma of
264 healthy individuals¹⁷. Moreover, all the three forms of immunoglobulins can bind to the

265 same region of the FN1 protein¹⁶. An inverse correlation between increasing circulating FN1
266 levels and decreased IgM responses against FN1 were previously documented during
267 Trypanosoma infection¹⁸. Hence, we argued that IgM against FN1 possibly belongs to the
268 natural IgM ((n)IgM) category. Natural IgM are key immunoglobulins produced specifically by
269 plasma B1 B cells¹⁹ and have important scavenger and protector function²⁰. Decreased
270 (n)IgM can be the source for autoimmunity¹⁹. As a proof of concept, we validated the
271 microarray results using immunoblotting with purified human pFN1 and recombinant FN1.2
272 proteins as a bait, in 7 severe ME/CFS, 5 long COVID and 5 healthy controls, which confirmed
273 the microarray data showing undetectable or poorly detectable amounts of IgM-FN1
274 (Extended Fig. 5e) in severe ME/CFS and long COVID patients. IgM-FN1 was detectable in
275 healthy controls. It is noteworthy that human IgM detected only the full-length pFN1. For a
276 quantitative analysis, we further developed sandwich ELISA assays to measure serum IgM
277 and IgG levels against human FN1 and measured both in healthy controls (n=63), ME/CFS
278 (n=66) and three different groups of SARS-CoV-2 positive patients (no LC, n=55; mild LC,
279 n=63; severe LC, n=22). The total IgM-FN1 levels were not different between healthy
280 controls and ME/CFS patients (Fig. 3a). However, SARS CoV-2 positive patients showed
281 significantly decreased IgM-FN1 levels in comparison to both healthy controls and ME/CFS
282 patients (Fig. 3a, HC vs No LC, HC vs mild LC, HC vs severe LC, ****P < 0.00001. No LC vs
283 severe LC, *P = 0.0376). Furthermore, IgM-FN1 amounts correlated with long COVID severity
284 with the strongest decrease in severe LC patients (Fig. 3a). Similarly, IgG against FN1 was also
285 significantly decreased in all the three groups of SARS-CoV-2 positive patients (Fig. 3b, HC vs
286 No LC, HC vs mild LC, HC vs severe LC, ****P < 0.00001). Severe LC patients showed a trend
287 towards recovery of IgG-FN1 levels. Further separation of ME/CFS patients based on disease
288 severity (Bell score), showed significantly decreased IgM-FN1 levels only in severe patients
289 with a Bell score between 0-20 (Fig. 3c, HC vs Bell 0-20, **P = 0.0046. Bell 0-20 vs Bell 30-50,
290 ***P = 0.0002). IgG-FN1 did not show any association with ME/CFS disease severity (Fig. 3d).
291 To answer whether specifically (n)IgM against fibronectin was depleted post SARS-CoV-2
292 infection or not, we tested two of the most common (n)IgMs against phosphoryl choline (PC)
293 and Malondialdehyde (MDA) in a small cohort of healthy controls and all the three groups of
294 SARS-CoV-2 positive patients (n=20 for each group). Both IgM-PC and IgM-MDA levels
295 showed a significant correlation with long COVID severity (Fig. 3e-f, Extended Fig. 6a-b)
296 being the lowest in severe LC patients. AUROC analysis of IgM-FN1 also showed increased

297 detection accuracy as the severity of long COVID increased from no LC to severe LC (Fig. 3g-
298 i). Multi-variate ROC analysis using both circulating FN1 and IgM-FN1 levels showed that both
299 these proteins together can potentially serve as a biomarker for severe ME/CFS (Fig. 4a,
300 accuracy of 83.7%) and severe long COVID (Fig. 4b, accuracy of 85.3%). Multiple logistic
301 regression analysis separated healthy controls from severe ME/CFS patients based on both
302 FN1 and IgM-FN1 levels with 83.7% accuracy (Fig. 4c) and healthy controls from both mild
303 and severe long COVID patients with 83.3% accuracy (Fig. 4d). Moreover, both ME/CFS and
304 long COVID patients showed close similarity in terms of their FN1 and IgM-FN1 amounts
305 (Fig. 4e). In fact, severe groups of both ME/CFS and long COVID patients closely resembled
306 each other (Fig. 4f). Interestingly, all the three natural IgMs, i.e., (n)IgM-FN1, (n)IgM-PC and
307 (n)IgM-MDA levels showed a trend towards being more abundant in healthy females than
308 males (Extended Fig. 7a-b). In fact, female ME/CFS patients showed a significant decrease in
309 IgM-FN1 than male patients (Extended Fig. 7a) which was insignificant among other patient
310 groups. All the natural IgM levels were significantly lower in all three groups of LC patients
311 (Extended Fig. 7c) in comparison to healthy controls and had no clear association with
312 gender. In summary, our results show strong depletion of (n)IgMs following SARS-CoV-2
313 infection even after 6 months post-virus infection. Significantly increased circulating
314 fibronectin levels together with the decreased (n)IgM response against fibronectin has the
315 potential to separate SARS-CoV-2 infected non-long COVID individuals from long COVID and
316 severe ME/CFS patients.

317

318 **Discussion**

319 Chronic post viral illnesses like ME/CFS and long COVID affect multiple body systems and
320 may lead to development of overlapping clinical features with other known health
321 conditions making the diagnosis and treatment difficult for clinicians. No biomarker has
322 been identified for either of the conditions to date¹. Our study found increased humoral
323 response against HSV-1, HHV-6 and EBV dUTPases in ME/CFS patients and the same against
324 HSV-1 and EBV in long COVID patients suggesting herpesvirus reactivation as a potential
325 contributor to both the clinical conditions. These results support our previous studies in
326 ME/CFS patients²¹ and corroborate findings from other labs³ showing frequent EBV
327 reactivation post COVID-19 infection. Chronic herpesvirus infection contributes to

328 autoimmunity^{12,13}. Heightened expression of EBV dUTPase protein in plasma cell aggregates
329 near glomeruli was shown in kidney biopsy tissue from lupus nephritis (LN) patients (class III
330 and IV) undergoing flares that also exhibit an enrichment of long-lived autoantibody
331 producing memory plasma cells in the kidneys²², which are believed to contribute to disease
332 pathogenesis. Interestingly, the terminal differentiation of memory B-cells into plasma cells
333 causes reactivation of latent EBV resulting in the expression of the dUTPase^{23,24}. The
334 TLR2/MyD88/miRNA155/Ets-1 pathway is required to produce autoantibodies that form
335 DNA-containing immune complexes (IgG anti-ssDNA, IgG anti-dsDNA)²⁵ and EBV dUTPase is
336 a potent activator of TLR2/MyD88 signaling and inducer of pro-inflammatory cytokines and
337 miR155. In some ME/CFS patients exhibiting a dysfunctional GC Ab response, EBV dUTPase
338 may contribute to this process by stimulating an extrafollicular Ab response that promotes
339 increased splenic iNKTfH and marginal zone B cells, which could result in the formation of
340 autoreactive B cells and, subsequently, the production of autoreactive Abs²⁶. Interestingly,
341 the dUTPase protein is also released in exosomes from EBV-infected B cells (plasma cells)
342 during abortive lytic replication of EBV and these dUTPase-containing exosomes induced the
343 production of pro-inflammatory cytokines in dendritic cells and PBMCs by engaging TLR2²⁷.
344 We argue that herpesvirus dUTPases post virus reactivation can play a contributing role in
345 disease development. We have recently shown presence of EBV dUTPase proteins within
346 brain biopsies of ME/CFS patients⁵ supporting the notion that strong neurological symptoms
347 of ME/CFS potentially can be due to herpesviruses like HHV-6, EBV reactivating within
348 specific tissues²⁸. However, nearly uniform levels of depletion of IgM-FN1 and IgG-FN1 in all
349 the SARS-CoV-2 positive patients studied suggest that herpesvirus reactivation alone can't
350 be responsible for the disease development. At the same time, a decrease in the IgG
351 response against HHV-6 dUTPase in long COVID patients (Fig. 1b) could suggest alterations in
352 the B cell response against specific pathogenic antigens post SARS-CoV-2 infection. We argue
353 that ME/CFS and long COVID are post viral illnesses where the origin of the disease and
354 acute post-infectious clinical features are potentially different. But both the diseases seem
355 to overlap with each other sharing similar secondary chronic clinical features (Extended Fig.
356 8).

357

358 Endothelial cell dysfunction is a key clinical feature of both ME/CFS²⁹ and long COVID³⁰. In
359 this study, immunoglobulins isolated from severe ME/CFS patients induced alterations in

360 mitochondrial morphology of cultured primary cells favoring a fragmented mitochondrial
361 phenotype. Further proteomic characterization of isolated immunoglobulins and associated
362 circulating immune complexes (CIC) revealed decreased presence of three proteins within
363 the IgG-bound CIC (namely TF, A2M and FN1), FN1 levels showing the clearest differences to
364 that from healthy individuals. On the other hand, circulating FN1 was significantly increased
365 in serum of ME/CFS patients. Atherosclerosis associated inflammation shows deposition of
366 fibronectin in endothelial cells³¹. Antigens that bind to mesangial fibronectin induce
367 glomerulonephritis through immune complex formations³². Plasma fibronectin is targeted by
368 several bacteria including *Borrellia burgdorferi*³³ and *S. aureus*³⁴ for cell colonization. On the
369 other hand, antibody response develops against plasma fibronectin specifically bound to
370 early *Borrellia* antigen RevA³⁵. Fibronectin is an essential component of circulating immune
371 complexes³⁶ because of its interaction with complement proteins like C1q³⁷ and C3 that
372 protect against pathogenic infections³⁸. Hence, our finding of decreased fibronectin within
373 immune complexes of ME/CFS patients could suggest poor bacterial and other pathogen
374 clearance. Significantly increased circulating fibronectin in ME/CFS and long COVID patients
375 was positively correlated with disease severity. Circulating fibronectin binds to TLR4 and
376 induces an inflammatory cytokine response³⁹. Specific domains of fibronectin also activate
377 platelets⁴⁰ and mast cells⁴¹. Increased serum/plasma fibronectin is commonly detected in
378 rheumatic diseases³⁶ and is suggested to be the cause of polyclonal activation of B cells⁴².
379 Interestingly, irrespective of disease groups, female patients showed significantly increased
380 circulating FN1 protein levels compared to male patients (Extended Fig. 5b) suggesting a
381 possibility to reach the pathological threshold sooner than males. Increased circulating
382 fibronectin levels are correlated with low levels of IgM against fibronectin during
383 *Trypanosoma* infection¹⁸. Using different experimental approaches, we showed depletion of
384 IgM against fibronectin as a characteristic feature of severe ME/CFS and long COVID
385 suggesting depletion of IgM-FN1 as a key contributor to disease severity.

386

387 Natural IgM are critical players in maintaining cellular homeostasis through their scavenger,
388 protector, and regulator function^{20,43}. Protection against cellular debris that can cause
389 development of autoimmunity is a key function of (n)IgM. We argue that IgM against
390 fibronectin (IgM-FN1) belongs to the (n)IgM category as IgM-FN1 is frequently detected in
391 plasma of healthy individuals¹⁷. Our results showed presence of abundant IgM against FN1

392 in serum of healthy individuals supporting the notion that IgM-FN1 might belong to the
393 natural IgM category and is crucial in complement activation and protection against
394 autoimmunity. We showed that (n)IgM-FN1 binds only to full-length plasma fibronectin and
395 does not have specificity for cellular fibronectin. As we found decreased fibronectin within
396 the immune complexes of ME/CFS patients, we argue that severe ME/CFS and possibly long
397 COVID patients have compromised complement activation against fibronectin leading to
398 poor pathogen clearance and poor scavenging abilities against apoptotic cells causing
399 generation of a broad range of autoimmune antibodies. Additionally, we noticed a decrease
400 in two of the most common (n)IgMs against PC and MDA in SARS-CoV-2 positive patient
401 cohorts, which strengthens the idea that loss of natural IgMs might be the cause of
402 autoimmunity in both ME/CFS and long COVID patients. Additionally, we observed that
403 females tend to have increased (n)IgM levels than males supporting the idea of immune
404 differences between both genders⁴⁴. These differences in circulating FN1 levels among male
405 and female patients as well as gender-dependent differences in (n)IgM levels might explain
406 the predominance of both ME/CFS and long COVID among females compared to males¹.

407 Natural antibodies (IgM, IgG and IgA) are produced by innate-like B cells like B1, B2, and
408 marginal zone (MZ) B cells⁴⁵. (n)IgMs are specifically produced by B1 B cells within bone
409 marrow and other primary lymphoid tissues¹⁹ and by circulating CD20⁺CD38^{hi} B cells⁴⁶. We
410 argue that under specific yet to be understood conditions, infection-mediated alterations
411 within primary hematopoietic organs might lead to alterations in B1 B cells (Extended Fig. 8),
412 which can eventually lead to depletion of natural IgM and development of autoimmunity.
413 Measles virus also depletes memory B cells by an unknown mechanism leading to 'immune
414 amnesia'⁴⁷. Another potential reason for depletion of (n)IgM can be alterations in CD4⁺ T
415 cells. Non-cognate CD4⁺ T cells, which help plasma B1 cells in mice to generate a unique
416 repertoire of (n)IgM⁴⁸. Furthermore, CXCR4⁺ regulatory CD4⁺ T (Treg) cells manipulate both
417 serum IgM levels and (n)IgM production by B1 B cells in the bone marrow⁴⁹. T cell
418 exhaustion and alterations in Treg numbers are documented in ME/CFS⁵⁰. Hence modulation
419 of T cell biology within primary hematopoietic tissues can have a potential impact on plasma
420 B1 B cells and (n)IgM levels.

421 In summary, our findings reveal depletion of (n)IgM to be associated with disease severity in
422 ME/CFS and long COVID, which may point to an autoimmune mechanism. Autoimmunity is
423 considered as a key causal factor for diseases like ME/CFS. Hence first therapeutic

424 interventions have been targeted to deplete pathogenic autoantibodies or B cells. In this
425 regard our findings have immediate implications in both ME/CFS and long COVID diagnosis
426 and further development of autoantibody treatment.

427

428 **References:**

- 429 1 Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings,
430 mechanisms and recommendations. *Nat Rev Microbiol* **21**, 133-146,
431 doi:10.1038/s41579-022-00846-2 (2023).
- 432 2 Banko, A., Miljanovic, D. & Cirkovic, A. Systematic review with meta-analysis of active
433 herpesvirus infections in patients with COVID-19: Old players on the new field. *Int J*
434 *Infect Dis* **130**, 108-125, doi:10.1016/j.ijid.2023.01.036 (2023).
- 435 3 Klein, J. *et al.* Distinguishing features of Long COVID identified through immune
436 profiling. *medRxiv*, doi:10.1101/2022.08.09.22278592 (2022).
- 437 4 Rasa, S. *et al.* Chronic viral infections in myalgic encephalomyelitis/chronic fatigue
438 syndrome (ME/CFS). *J Transl Med* **16**, 268, doi:10.1186/s12967-018-1644-y (2018).
- 439 5 Kasimir, F. *et al.* Tissue specific signature of HHV-6 infection in ME/CFS. *Front Mol*
440 *Biosci* **9**, 1044964, doi:10.3389/fmolb.2022.1044964 (2022).
- 441 6 Bahmer, T. *et al.* Severity, predictors and clinical correlates of Post-COVID syndrome
442 (PCS) in Germany: A prospective, multi-centre, population-based cohort study.
443 *EClinicalMedicine* **51**, 101549, doi:10.1016/j.eclinm.2022.101549 (2022).
- 444 7 Hartung, T. J. *et al.* Fatigue and cognitive impairment after COVID-19: A prospective
445 multicentre study. *EClinicalMedicine* **53**, 101651, doi:10.1016/j.eclinm.2022.101651
446 (2022).
- 447 8 Tondera, D. *et al.* SLP-2 is required for stress-induced mitochondrial hyperfusion. *The*
448 *EMBO Journal* **28**, 1589-1600, doi:10.1038/emboj.2009.89 (2009).
- 449 9 Das, R. & Chakrabarti, O. Mitochondrial hyperfusion: a friend or a foe. *Biochem Soc*
450 *Trans* **48**, 631-644, doi:10.1042/BST20190987 (2020).
- 451 10 Cai, M. *et al.* Characterization of the subcellular localization of Epstein-Barr virus
452 encoded proteins in live cells. *Oncotarget* **8**, 70006-70034,
453 doi:10.18632/oncotarget.19549 (2017).
- 454 11 Menges, S. *et al.* Alpha-synuclein prevents the formation of spherical mitochondria
455 and apoptosis under oxidative stress. *Sci Rep* **7**, 42942, doi:10.1038/srep42942
456 (2017).
- 457 12 Houen, G. & Trier, N. H. Epstein-Barr Virus and Systemic Autoimmune Diseases. *Front*
458 *Immunol* **11**, 587380, doi:10.3389/fimmu.2020.587380 (2020).
- 459 13 Zhao, Z. S., Granucci, F., Yeh, L., Schaffer, P. A. & Cantor, H. Molecular mimicry by
460 herpes simplex virus-type 1: autoimmune disease after viral infection. *Science* **279**,
461 1344-1347, doi:10.1126/science.279.5355.1344 (1998).
- 462 14 Kadaja, L. *et al.* IgG from patients with liver diseases inhibit mitochondrial respiration
463 in permeabilized oxidative muscle cells: impaired function of intracellular energetic
464 units? *Mol Cell Biochem* **256-257**, 291-303,
465 doi:10.1023/b:mcbi.0000009876.23921.e6 (2004).

- 466 15 Cho, S. *et al.* Neuromyelitis optica (NMO)-IgG-driven organelle reorganization in
467 human iPSC-derived astrocytes. *FASEB J* **35**, e21894, doi:10.1096/fj.202100637R
468 (2021).
- 469 16 Rostagno, A. A., Frangione, B. & Gold, L. Biochemical studies on the interaction of
470 fibronectin with Ig. *J Immunol* **146**, 2687-2693 (1991).
- 471 17 Bray, B. A., Osman, M. & Turino, G. M. Evidence that fibronectin-immunoglobulin
472 complexes occur normally in plasma. *Proc Soc Exp Biol Med* **207**, 324-331,
473 doi:10.3181/00379727-207-43823 (1994).
- 474 18 Truyens, C., Rivera, M. T., Ouaiissi, A. & Carlier, Y. High circulating levels of fibronectin
475 and antibodies against its RGD adhesion site during mouse *Trypanosoma cruzi*
476 infection: relation to survival. *Exp Parasitol* **80**, 499-506, doi:10.1006/expr.1995.1062
477 (1995).
- 478 19 Baumgarth, N. The double life of a B-1 cell: self-reactivity selects for protective
479 effector functions. *Nat Rev Immunol* **11**, 34-46, doi:10.1038/nri2901 (2011).
- 480 20 Ehrenstein, M. R. & Notley, C. A. The importance of natural IgM: scavenger, protector
481 and regulator. *Nat Rev Immunol* **10**, 778-786, doi:10.1038/nri2849 (2010).
- 482 21 Halpin, P. *et al.* Myalgic encephalomyelitis/chronic fatigue syndrome and gulf war
483 illness patients exhibit increased humoral responses to the herpesviruses-encoded
484 dUTPase: Implications in disease pathophysiology. *J Med Virol* **89**, 1636-1645,
485 doi:10.1002/jmv.24810 (2017).
- 486 22 Chu, V. T. *et al.* Systemic activation of the immune system induces aberrant BAFF and
487 APRIL expression in B cells in patients with systemic lupus erythematosus. *Arthritis*
488 *Rheum* **60**, 2083-2093, doi:10.1002/art.24628 (2009).
- 489 23 Al Tabaa, Y. *et al.* Functional Epstein-Barr virus reservoir in plasma cells derived from
490 infected peripheral blood memory B cells. *Blood* **113**, 604-611, doi:10.1182/blood-
491 2008-02-136903 (2009).
- 492 24 Laichalk, L. L. & Thorley-Lawson, D. A. Terminal differentiation into plasma cells
493 initiates the replicative cycle of Epstein-Barr virus in vivo. *J Virol* **79**, 1296-1307,
494 doi:10.1128/JVI.79.2.1296-1307.2005 (2005).
- 495 25 Wen, Z. *et al.* Autoantibody induction by DNA-containing immune complexes
496 requires HMGB1 with the TLR2/microRNA-155 pathway. *J Immunol* **190**, 5411-5422,
497 doi:10.4049/jimmunol.1203301 (2013).
- 498 26 Cox, B. S., Alharshawi, K., Mena-Palomo, I., Lafuse, W. P. & Ariza, M. E. EBV/HHV-6A
499 dUTPases contribute to myalgic encephalomyelitis/chronic fatigue syndrome
500 pathophysiology by enhancing TFH cell differentiation and extrafollicular activities.
501 *JCI Insight* **7**, doi:10.1172/jci.insight.158193 (2022).
- 502 27 Ariza, M. E., Rivallier, P., Glaser, R., Chen, M. & Williams, M. V. Epstein-Barr virus
503 encoded dUTPase containing exosomes modulate innate and adaptive immune
504 responses in human dendritic cells and peripheral blood mononuclear cells. *PLoS*
505 *One* **8**, e69827, doi:10.1371/journal.pone.0069827 (2013).
- 506 28 Lerner, A. M. *et al.* Antibody to Epstein-Barr virus deoxyuridine triphosphate
507 nucleotidohydrolase and deoxyribonucleotide polymerase in a chronic fatigue
508 syndrome subset. *PLoS One* **7**, e47891, doi:10.1371/journal.pone.0047891 (2012).
- 509 29 Sandvik, M. K. *et al.* Endothelial dysfunction in ME/CFS patients. *PLoS One* **18**,
510 e0280942, doi:10.1371/journal.pone.0280942 (2023).

- 511 30 Ahamed, J. & Laurence, J. Long COVID endotheliopathy: hypothesized mechanisms
512 and potential therapeutic approaches. *J Clin Invest* **132**, doi:10.1172/JCI161167
513 (2022).
- 514 31 Al-Yafeai, Z. *et al.* Endothelial FN (Fibronectin) Deposition by alpha5beta1 Integrins
515 Drives Atherogenic Inflammation. *Arterioscler Thromb Vasc Biol* **38**, 2601-2614,
516 doi:10.1161/ATVBAHA.118.311705 (2018).
- 517 32 Cosio, F. G., Mahan, J. D. & Sedmak, D. D. Experimental glomerulonephritis induced
518 by antigen that binds to glomerular fibronectin. *Am J Kidney Dis* **15**, 160-168,
519 doi:10.1016/s0272-6386(12)80514-2 (1990).
- 520 33 Niddam, A. F. *et al.* Plasma fibronectin stabilizes *Borrelia burgdorferi*-endothelial
521 interactions under vascular shear stress by a catch-bond mechanism. *Proceedings of*
522 *the National Academy of Sciences of the United States of America* **114**, E3490-E3498,
523 doi:10.1073/pnas.1615007114 (2017).
- 524 34 Chen, H. Y., Lin, M. H., Chen, C. C. & Shu, J. C. The expression of fibronectin is
525 significantly suppressed in macrophages to exert a protective effect against
526 *Staphylococcus aureus* infection. *BMC Microbiol* **17**, 92, doi:10.1186/s12866-017-
527 1003-9 (2017).
- 528 35 Brissette, C. A. *et al.* The borrelial fibronectin-binding protein RevA is an early antigen
529 of human Lyme disease. *Clin Vaccine Immunol* **17**, 274-280, doi:10.1128/CVI.00437-
530 09 (2010).
- 531 36 Herbert, K. E. *et al.* Fibronectin and immune complexes in rheumatic diseases. *Ann*
532 *Rheum Dis* **46**, 734-740, doi:10.1136/ard.46.10.734 (1987).
- 533 37 Bing, D. H., Almeda, S., Isliker, H., Lahav, J. & Hynes, R. O. Fibronectin binds to the
534 C1q component of complement. *Proceedings of the National Academy of Sciences of*
535 *the United States of America* **79**, 4198-4201, doi:10.1073/pnas.79.13.4198 (1982).
- 536 38 Sandig, H. *et al.* Fibronectin is a TH1-specific molecule in human subjects. *The Journal*
537 *of allergy and clinical immunology* **124**, 528-535, 535 e521-525,
538 doi:10.1016/j.jaci.2009.04.036 (2009).
- 539 39 Kelsh, R., You, R., Horzempa, C., Zheng, M. & McKeown-Longo, P. J. Regulation of the
540 innate immune response by fibronectin: synergism between the III-1 and EDA
541 domains. *PLoS One* **9**, e102974, doi:10.1371/journal.pone.0102974 (2014).
- 542 40 Thurlow, P. J., Kenneally, D. A. & Connellan, J. M. The role of fibronectin in platelet
543 aggregation. *Br J Haematol* **75**, 549-556, doi:10.1111/j.1365-2141.1990.tb07797.x
544 (1990).
- 545 41 Gondokaryono, S. P. *et al.* The extra domain A of fibronectin stimulates murine mast
546 cells via toll-like receptor 4. *J Leukoc Biol* **82**, 657-665, doi:10.1189/jlb.1206730
547 (2007).
- 548 42 Dziarski, R. Modulation of polyclonal activation by plasma fibronectin and fibronectin
549 fragments. *Immunology* **61**, 111-116 (1987).
- 550 43 Gronwall, C., Vas, J. & Silverman, G. J. Protective Roles of Natural IgM Antibodies.
551 *Front Immunol* **3**, 66, doi:10.3389/fimmu.2012.00066 (2012).
- 552 44 Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. *Nat Rev Immunol*
553 **16**, 626-638, doi:10.1038/nri.2016.90 (2016).
- 554 45 Panda, S., Zhang, J., Tan, N. S., Ho, B. & Ding, J. L. Natural IgG antibodies provide
555 innate protection against ficolin-opsonized bacteria. *The EMBO Journal* **32**, 2905-
556 2919, doi:10.1038/emboj.2013.199 (2013).

- 557 46 Quach, T. D. *et al.* Distinctions among Circulating Antibody-Secreting Cell Populations,
558 Including B-1 Cells, in Human Adult Peripheral Blood. *J Immunol* **196**, 1060-1069,
559 doi:10.4049/jimmunol.1501843 (2016).
- 560 47 Mina, M. J. *et al.* Measles virus infection diminishes preexisting antibodies that offer
561 protection from other pathogens. *Science* **366**, 599-606,
562 doi:10.1126/science.aay6485 (2019).
- 563 48 Smith, F. L. *et al.* B-1 plasma cells require non-cognate CD4 T cell help to generate a
564 unique repertoire of natural IgM. *J Exp Med* **220**, doi:10.1084/jem.20220195 (2023).
- 565 49 Elias, S. *et al.* CXCR4+ Treg cells control serum IgM levels and natural IgM
566 autoantibody production by B-1 cells in the bone marrow. *J Exp Med* **219**,
567 doi:10.1084/jem.20220047 (2022).
- 568 50 Mandarano, A. H. *et al.* Myalgic encephalomyelitis/chronic fatigue syndrome patients
569 exhibit altered T cell metabolism and cytokine associations. *J Clin Invest* **130**, 1491-
570 1505, doi:10.1172/JCI132185 (2020).
- 571

572 **Acknowledgements:**

573 The study was carried out using the clinical-scientific infrastructure of NAPKON (Nationales
574 Pandemie Kohorten Netz, German National Pandemic Cohort Network) of the Network
575 University Medicine (NUM), funded by the Federal Ministry of Education and Research
576 (BMBF).

577 We gratefully thank all NAPKON sites who contributed patient data and/or biosamples for
578 this analysis. We also thank the NAPKON Steering Committee: University Hospital Giessen
579 and Marburg, Giessen (Herold S), University of Wuerzburg, Wuerzburg (Heuschmann P),
580 Charité - Universitätsmedizin Berlin, Berlin (Heyder R), University Medicine Greifswald,
581 Greifswald (Hoffmann W), Hannover Unified Biobank, Hannover Medical School, Hannover
582 (Illig T), University Hospital Schleswig-Holstein, Kiel (Schreiber S), University Hospital
583 Cologne and University Hospital Frankfurt, Cologne and Frankfurt (Vehreschild JJ), Jena
584 University Hospital, Jena (von Lilienfeld-Toal M), Charité - Universitaetsmedizin Berlin, Berlin
585 (Witzenrath M).

586 We would like to thank the Core Unit for Confocal Microscopy and Flow Cytometry-based
587 Cell Sorting of the IZKF Würzburg for supporting the study. We thank Uta Behrends,
588 Technische Universität München (TUM) for kindly providing ME/CFS and healthy control
589 samples for this study. We thank Timo Ludwig for providing demographics from STAAB
590 database.

591

592 **Funding:**

593 We thank Amar Foundation, USA for a career development grant (BKP), ME Research UK
594 (BKP) and Bundesministerium für Bildung und Forschung (BMBF) (grant number 01EJ2204E)
595 (BKP) for supporting this work. This research was also supported by the National Institutes
596 of Health (NIH/NIAID), USA, grant RO1AI084898-06 (MEA and MW) and The infectious
597 Diseases Society of America (IDSA) Foundation, USA, grant (MEA). The COVIDOM study is
598 part of the National Pandemic Cohort Network (NAPKON). NAPKON is funded by COVID-19-
599 related grants from the Network University Medicine (NUM; NAPKON grant number:
600 01KX2021). Parts of the infrastructure of the Würzburg study site was funded by the federal
601 state of Bavaria. The STAAB Cohort study was supported by the German Ministry of Research
602 and Education within the Comprehensive Heart Failure Centre Würzburg (BMBF 01EO1004
603 and 01EO1504). This study was, further, supported by the German Research Foundation

604 (DFG) through the Comprehensive Research Center 1525 'Cardio-immune interfaces'
605 (453989101, project C5) (CM and NB) and the Interdisciplinary Center for Clinical Research -
606 IZKF Würzburg (advanced clinician-scientist program; AdvCSP 3) (CM).

607

608 **Author Contribution:**

609 BKP conceived the idea, developed and supervised the project. ZL, CH, AG, AK carried out
610 majority of experiments; IMP carried out autophagosome work; SK carried out multivariate
611 and other statistical data analysis; AH, CN, VC, BA, TB, SC, JJV, OM, CS, KL, KT, JR, FE, LS, PUH,
612 SS, CM, FS, CS, NB, SK, GR contributed with patient recruitment, sample collection, patient
613 data management; MEA and MW contributed with important reagents and experiments; AS
614 and SL carried out mass spectrometry studies and related data analysis, RN supervised
615 mitochondrial experimental work, analyzed the data. BKP drafted the manuscript with help
616 from MEA. All other authors critically revised the manuscript. All authors approved the
617 submitted version.

618

619 **Competing Interests:**

620 The authors declare that they have no competing interests.

621

622 **Materials availability:**

623 Further information and requests for resources and reagents should be directed to Bhupesh
624 K Prusty (bhupesh.prusty@uni-wuerzburg.de).

625

626 **Data availability:**

627 The mass spectrometry proteomics data for the serum immunoglobulin proteome study
628 have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository
629 with the dataset identifier PXD041945 and the same for HEK293 dUTPase co-IP proteome
630 study with the dataset identifier PXD041942. All the experimental data are deposited to
631 Mendley (doi: 10.17632/4xkft5g9r5.1).

632

633 **Figure legends:**

634

635 **Fig. 1: Reactivation of EBV in ME/CFS and long COVID patients and the role of viral**
636 **dUTPase protein in cellular manipulation.**

637 **a.** Immunoblot based detection of IgG against herpesvirus dUTPase in human serum. Virus-
638 specific recombinant protein bands detected by IgG are indicated.

639 **b.** Likert chart showing percentage of positivity for antibodies against EBV, HSV-1 and HHV-6
640 dUTPase within healthy controls (HC), ME/CFS, Covid-19 PCR positive but without long
641 COVID (No LC), mild LC and severe LC patients. Kruskal Wallis (and its higher order
642 equivalent, ScheirerRayHare Test) rank sum test for antibody state. EBV, *P = 0.015; HSV-1,
643 *P = 0.068; HHV-6, **P = 0.002.

644 Mann-Whitney non-parametric test for EBV dUTPase HC vs ME/CFS, ***P = 0.0008; for HSV-
645 1 dUTPase HC vs severe LC, P = 0.051; for HSV-1 dUTPase No LC vs severe LC, *P = 0.013.

646 Different amounts IgG levels in patient serum was arbitrarily divided into 4 groups (0,
647 absent; 1, low; 2, moderate; 3, high).

648 **c.** Confocal images shows hyperpolarization of mitochondria in HEK293 cells under transient
649 expression of HSV-1, HHV-6 and EBV dUTPases. Mock vector backbone was used as a
650 control.

651 **d.** Average mitochondrial surface area from 5 biological replicates are plotted in the form of
652 a scatter plot. n=5. Unpaired two-tailed non-parametric t-test. Mock vs EBV dUTPase, *P =
653 0.0414; Mock vs HHV-6 dUTPase, **P = 0.0077; Mock vs HSV-1 dUTPase, *P = 0.0479.

654 **e.** Immunoblot analysis shows increase in mitofusin1 (Mfn1) and decrease in LC3 β protein
655 levels in presence of herpesvirus dUTPases. GAPDH staining was used as a loading control.

656 Mean Mfn1 and LC3 β protein levels are presented as scatter plots. Data from 3 independent

657 experiments. n=3. Unpaired two-tailed non-parametric t-test. For Mfn1, *P = 0.03 (Mock vs
658 HHV-6); *P = 0.01 (Mock vs HSV-1). For LC3 β , *P = 0.01 (Mock vs EBV); *P = 0.05 (Mock vs
659 HHV-6).

660 **f.** EBV dUTPase interferes with autophagosome assembly.

661 **g.** TMRE dyes were used to study mitochondrial membrane potential and OXPHOS in
662 HEK293 cells. Cells were transiently transfected with herpesvirus dUTPases or a mock vector
663 for 48 h. Trypsinized cells were stained with TMRE dye and were used for flow cytometry.
664 Oligomycin was used to inhibit ATP synthase. Data from 3 independent experiments. n=3.
665 MFI, mean fluorescence intensity.

666 **h.** Normalized log₂ ratio of LFQ (label-free quantitation) intensities of proteins. Fold change
667 of proteins in HSV-1 vs Mock was plotted against the same in EBV vs Mock to highlight
668 proteins that were common and were enriched in both sample sets. Circles indicate
669 identified cellular proteins; circle size correlates with the number of razor and unique
670 peptides used for quantification. Significantly enriched proteins that are potential
671 interaction partners of EBV and HSV-1 dUTPases are displayed in red.

672 **i.** Immunoblot analysis to validate potential herpesvirus dUTPase interacting partners
673 identified from co-IP. GAPDH staining was used as a negative control.

674

675 **Fig. 2: Autoimmunity, mitochondrial alterations and circulating Fibronectin levels in**
676 **ME/CFS.**

677 **a.** Confocal images show mitochondrial architecture in primary HUVEC cells exposed to 1 μ g
678 of purified IgG from patient sera. Two different representative images for each condition is
679 shown.

680 **b.** Average mitochondrial surface area in primary HUVEC cells exposed to 1 μ g of purified IgG
681 from patient sera is quantified and compared between healthy controls, mild/moderate,
682 severe ME/CFS. Data from three independent experiments from each serum sample is
683 shown as a violin plot. n=3. Two-tailed non-parametric test. Healthy control vs
684 mild/moderate ME/CFS, *P = 0.0329. Healthy control vs severe ME/CFS, **P = 0.0046.
685 Mild/moderate vs severe ME/CFS, ****P < 0.0001.

686 **c.** Immunoblot analysis shows decrease in mitofusin1 (Mfn1) and PLD6 protein levels in
687 HUVEC cells exposed to 1 μ g of purified IgG from patient sera for 12 h. Actin staining was
688 used as a loading control. Fold change values were derived from densitometric analysis of
689 bands after normalization with the same for actin. n=2. HD, healthy donors; CFS, severe CFS
690 patients.

691 **d.** Heat map of log₂ fold LFQ intensities of proteins detected within purified immune
692 complexes from patient sera. Three proteins that showed differential protein levels between
693 healthy controls and ME/CFS patients are shown.

694 **e.** Multivariate analysis of clusters based on distance metrics derived from IgM antibody
695 levels for a panel of autoantigens. Log-transformed scaled data showing relative differences
696 between different variable in both healthy controls and patients.

697 **f.** The Variables Factor map for the Principal Components (for Patients and Healthy Controls
698 combined data) shows the projection of the top 10 Autoantigen variables projected onto the
699 plane spanned by the first two Principal Components.

700 **g.** Serum fibronectin (FN1) levels in patient sera. Log₂ values of FN1 are presented as a violin
701 plot. Two-tailed parametric t-test. Healthy control (HC) vs ME/CFS, **P = 0.005.

702 **h.** Kernel density plot showing the bivariate serum FN1 distributions among healthy controls
703 and ME/CFS patients. FN1 concentrations on both X- and Y-axis are presented as μ g/ml.

704 i. Circulating fibronectin (FN1) levels correlates with ME/CFS severity associated Bell score.

705 Log2 fold FN1 vales are presented as a violin plot. Two-tailed parametric t-test. HC vs Bell 0-

706 20, ****P < 0.0001. Bell 0-20 vs Bell 30-50, **P = 0.0032.

707 j. AUROC analysis for circulating FN1 levels in healthy controls (HC) vs severe ME/CFS

708 patients.

709 k. Serum fibronectin (FN1) levels in different patient groups post SARS-CoV-2 infection. Log2

710 values of FN1 are presented as a violin plot. Two-tailed parametric t-test. Healthy control

711 (HC) vs mild LC, **P = 0.0032. HC vs severe LC, *P = 0.0488. ns, not significant.

712

713 **Fig. 3: IgM and IgG levels against Fibronectin in ME/CFS and long COVID.**

714 a. IgM levels against fibronectin (IgM-FN1) in patient sera. Log2 fold IgM-FN1 amounts are

715 presented as a violin plot. Two-tailed parametric t-test. Healthy control (HC) vs SARS CoV-2

716 positive but without long COVID (No LC), HC vs mild LC, HC vs severe LC, ****P < 0.00001.

717 No LC vs severe LC, *P = 0.0376. ns, not significant.

718 b. IgG levels against fibronectin (IgM-FN1) in patient sera. Log2 fold IgG-FN1 amounts are

719 presented as a violin plot. Two-tailed parametric t-test. Healthy control (HC) vs SARS CoV-2

720 positive but without long COVID (No LC), HC vs mild LC, HC vs severe LC, ****P < 0.00001.

721 ns, not significant.

722 c. IgM-fibronectin (FN1) levels correlates with ME/CFS severity associated Bell scores. Log2

723 fold IgM-FN1 vales are presented as a violin plot. Two-tailed parametric t-test. HC vs Bell 0-

724 20, **P = 0.0046. Bell 0-20 vs Bell 30-50, ***P = 0.0002.

725 d. IgG-fibronectin (FN1) levels does not correlate with ME/CFS severity associated Bell

726 scores. Log2 fold IgG-FN1 vales are presented as a violin plot. Two-tailed parametric t-test.

727 Ns, not significant.

728 **e.** IgM levels against phosphorylcholine (IgM-PC) in patient sera. Log₂ fold IgM-PC amounts
729 are presented as a violin plot. Two-tailed parametric t-test. Healthy control (HC) vs mild LC,
730 ***P = 0.0002. HC vs severe LC, ***P = 0.0006. No LC vs severe LC, *P = 0.0216. No LC vs
731 mild LC, *P = 0.0111. ns, not significant.

732 **f.** IgM levels against malondialdehyde (IgM-MDA) in patient sera. Log₂ fold IgM-MDA
733 amounts are presented as a violin plot. Two-tailed parametric t-test. Healthy control (HC) vs
734 mild LC, *P = 0.0175. HC vs severe LC, ***P = 0.0068. No LC vs severe LC, *P = 0.0209. No LC
735 vs mild LC, *P = 0.0525. ns, not significant.

736 **g.** AUROC analysis for IgM-FN1 levels in healthy controls (HC) vs SARS CoV-2 positive but
737 without long COVID (No LC) patients.

738 **h.** AUROC analysis for IgM-FN1 levels in healthy controls (HC) vs mild LC patients.

739 **i.** AUROC analysis for IgM-FN1 levels in healthy controls (HC) vs severe LC patients.

740

741 **Fig. 4: IgM-FN1 and circulating fibronectin as a biomarker in ME/CFS and long COVID.**

742 **a.** Multi-variate AUROC analysis for circulating FN1 and IgM against fibronectin (IgM-FN1) in
743 healthy controls (HC) vs severe ME/CFS patients. Multiple logistic regression. ****P <
744 0.0001.

745 **b.** Multi-variate AUROC analysis for circulating FN1 and IgM against fibronectin (IgM-FN1) in
746 healthy controls (HC) vs severe LC patients. Multiple logistic regression. ****P < 0.0001.

747 **c.** Multiple variable bubble plot with circulating FN1 levels plotted against IgM-FN1 for
748 healthy controls (HC) and severe ME/CFS patients.

749 **d.** Multiple variable bubble plot with circulating FN1 levels plotted against IgM-FN1 for
750 healthy controls (HC) and total long COVID patients (mild LC + severe LC).

751 e. Multiple variable bubble plot with circulating FN1 levels plotted against IgM-FN1 for
752 ME/CFS and total long COVID patients (mild LC + severe LC).

753 f. Multiple variable bubble plot with circulating FN1 levels plotted against IgM-FN1 for
754 severe ME/CFS (with Bell 0-20) and severe long COVID patients.

755

756

757 **Supplementary Table 1:** Patient demographics.

758 **Supplementary Table 2:** List of antigens used in the microarray study.

759 **Supplementary Table 3:** List of plasmids used in the study.

760 **Supplementary Table 4:** List of antibodies used in the study.

761 **Supplementary Table 5:** Inter- and Intra-assay variations in IgM and IgG ELISA.

762

763

764

765

766

767 **Online-only Methods**

768 **Patient recruitment and serum collection**

769 **Long COVID patient cohort:** COVIDOM is a prospective, population-based cohort study to
770 investigate the long-term health sequelae of SARS-CoV-2 infection. Details have been
771 reported elsewhere^{1,2}. COVIDOM was approved by the local ethics committees of the
772 university hospitals of Kiel (No. D 537/20), and Würzburg (No. 236/20_z) and was registered
773 at clinicaltrials.gov (NCT04679584) and at the German Registry for Clinical Studies (DRKS,
774 DRKS00023742). COVIDOM participants of the Würzburg sub-cohort were recruited in the
775 catchment area of Würzburg and identified through local public health authorities so as to
776 address an unbiased subpopulation regarding age, sex, hospitalization, and media literacy.
777 Main inclusion criteria were (i) a polymerase chain reaction (PCR) confirmed SARS-CoV-2
778 infection and (ii) a period of at least 6 months between the infection and the visit to the
779 COVIDOM study site. During the on-site examination participants underwent detailed
780 cardio-pulmonary phenotyping and blood was drawn. Serum was stored at Interdisciplinary
781 Bank of Biomaterials and Data of the University Hospital of Würzburg (ibdw). Long COVID
782 severity was determined on the basis of a previously described scoring system¹.

783 **ME/CFS patient cohort:** ME/CFS patients, and gender- and age matched healthy controls
784 were diagnosed at the outpatient clinic at the Charité Universitätsmedizin, Berlin and
785 Technische Universität München (TUM) between 2020 and 2023. Diagnosis of ME/CFS in all
786 patients was based on the 2003 Canadian Consensus Criteria and exclusion of other medical
787 or neurological diseases that may cause fatigue by a comprehensive clinical and laboratory
788 evaluation. The study was approved by the Ethics Committee of Charité Universitätsmedizin
789 Berlin (EA2/067/20; EA2_066_22; EA4_174_22) and TUM (112/14 (healthy controls) and
790 529/18 (pediatric ME/CFS), 485/18 adult ME/CFS) in accordance with the 1964 Declaration
791 of Helsinki and its later amendments. Some of the patient samples were also collected at
792 University of California San Diego with signed informed consent under UCSD IRB Project
793 #140072, “The UCSD Metabolomics Study”. All patients gave informed consent. Whole
794 blood samples from each subject were allowed to clot at room temperature and then
795 centrifuged at 2000 x g for 10 min. The serum was stored in aliquots at -80°C.

796 **Healthy controls:** For long COVID studies, additional healthy controls were used from the
797 population-based Characteristics and Course of Heart Failure Stages A-B and Determinants
798 of Progression (STAAB) Cohort that recruited individuals without self-reported HF from the

799 general population of Würzburg, Germany, aged 30-79 years and stratified for age and sex.
800 The detailed study design and methodology have been published³. All study related
801 procedures were subjected to a rigid and regular quality control process⁴. The STAAB cohort
802 study protocol and procedures comply with the Declaration of Helsinki and received positive
803 votes from the Ethics Committee of the Medical Faculty as well as from the data protection
804 officer of the University of Würzburg (vote #98/13). All participants provided written
805 informed consent prior to any study examination. During the baseline visit, a fasting blood
806 sample was taken and serum was stored in the Interdisciplinary Bank of Biomaterials and
807 Data of the University Hospital of Würzburg (ibdw). For the current project, we identified a
808 random cohort of samples of STAAB participants, between the age 40 and 79 years. Overall
809 characteristics of the patient cohort is summarized in Supplementary Table 1.
810 For all the above-mentioned patient and healthy control study groups, there were no
811 statistically significant differences in age between male and female subjects except for
812 healthy controls ($p = 0.018$).

813

814 **Cell culture**

815 U2-OS (HTB-96), HEK293 (CRL-1573) cells were purchased from ATCC and HUVEC-TERT2 cells
816 (CHT-006-0008) were purchased from Evercyte, Austria. U2-OS and HEK293 cells were grown
817 in McCoy's 5A and DMEM media respectively supplemented with 10% (v/v) FBS and 200
818 units/ml penicillin-streptomycin. HUVEC-TERT2 cells were grown in EBM basal medium
819 (Lonza, Cat#CC-3121) supplemented with Components of EGM SingleQuot Kit (Lonza, Cat#
820 CC-4133: BBE, hEGF, hydrocortisone, ascorbic acid), 10% FBS and 20 $\mu\text{g}/\text{ml}$ G418. All cell
821 lines were cultured at 37 °C with 5% CO₂. Cells carrying stable GFP expression within
822 mitochondria were developed as mentioned before⁵. Cells stably expressing the
823 mitochondrial targeted GFP were created by cloning the mitochondrial targeted GFP into
824 pLVTHM vector backbone (Supplementary Table 3) and transducing target cells with the
825 lentivirus as mentioned before⁵. All the cell lines were frequently tested for Mycoplasma
826 contamination and were authenticated by sequencing, wherever necessary.

827

828 **dUTPase constructs, recombinant protein purification**

829 Constructs used in this study are detailed in Supplementary Table 3. Briefly, HSV-1 dUTPase
830 (UL50), HHV-6A dUTPase (U45) and EBV dUTPase (BLLF3) were cloned from bacterial

831 artificial chromosome (BAC) carrying the full-length viral genome. pFN22A vector backbone
832 was used to clone the viral dUTPases carrying N-terminal Halo-tag. All the constructs were
833 sequenced to confirm absence of mutations within the dUTPase open reading frames. A
834 mock dUTPase was created to be used as experimental control by digesting the pFN22A-
835 halo-HHV-6 dUTPase construct with XbaI restriction enzyme which removed majority of viral
836 dUTPase except for 186 bp N-terminal sequences. Digested construct was religated,
837 sequence verified and used as mock control.

838

839 For dUTPase recombinant protein preparation, bacterial Strain BL21 (DE3)plyS: F-, ompT,
840 hsdSB (rB-mB-) gal, dcm with chloramphenicol resistance was used. pTrcHIS vector (Thermo
841 Fischer Scientific) was selected using Ampicillin resistance. Depending on the particular
842 dUTPases constructs, bacterial pellets were obtained from 6 to 54 liters of Luria-Broth (LB)
843 culture. An overnight culture was prepared by inoculation of 100-200 µl of the bacterial
844 strain into 200 ml of LB medium containing ampicillin (100 µg/ml) and chloramphenicol (5
845 µg/ml). with shaking at 37 °C. Next day, a fresh inoculation was prepared by mixing 1 liter of
846 LB medium containing ampicillin and chloramphenicol with 20-25 ml of the overnight
847 culture and was incubated at 37 °C for 2 h with shaking. IPTG was added to the inoculated
848 medium at a concentration of 24 µg/ml with a further incubation of 2 h with shaking at 37
849 °C. Bacterial cells were centrifuge at 5000 rpm for 5 min and pellets were frozen down at -20
850 °C till protein extraction. On the day of protein preparation, thawed cell pellets were mixed
851 in column equilibration buffer (50 mM sodium phosphate, 300 mM NaCl and 10 mM
852 imidazole, pH 7.4), sonicated for 4 min (1 min burst; 1 min rest) on ice, centrifuged at 10,000
853 rpm for 30 min and the the supernatant was stored at 4 °C till the next day. HisPur™ Cobalt
854 3 ml spin columns were used under native conditions for protein purification. dUTPase
855 proteins were eluted with elution buffer (50 mM sodium phosphate, 300 mM NaCl and 150
856 mM imidazole, pH7.4).

857

858 **Average mitochondrial surface area and mitochondrial number analysis**

859 Software and modified algorithm for mitochondrial size and number measurement were
860 previously described by us in detail^{5,6}. All image-processing and analysis steps were
861 performed using Fiji⁷.

862

863 **Immunofluorescence Microscopy**

864 A detailed protocol for standard immunofluorescence microscopy is previously described⁸.

865 All the antibodies used in the immunofluorescence studies are described in Supplementary
866 Table 4. Halo-tagged dUTPase expression and cellular localization was visualized using Halo-
867 tag TMRDirect ligand (Promega, Cat. G2991).

868

869 **Immunoblotting**

870 Immunoblotting was carried out as described before^{8,9} using antibodies mentioned in
871 Supplementary Table 4. Equal protein loading was confirmed by using antibodies against β -
872 actin or GAPDH. All the primary antibodies were used at a dilution of 1:1000 and the HRP-
873 conjugated secondary antibodies were used at a dilution of 1:10,000.

874 a. **Western blot for detecting fibronectin in serum:** Serum samples were diluted 1:1 by
875 2X Laemmli buffer (100 mM Tris pH 6.8, 4% SDS, 0.2% bromophenol blue, 20% glycerol and
876 200 mM β -mercaptoethanol) and then further diluted 1:100 by 1X Laemmli buffer (50 mM
877 Tris pH 6.8, 2% SDS, 0.1% bromophenol blue, 10% glycerol and 100 mM β -mercaptoethanol).
878 10 μ l diluted serum samples were loaded onto 4-10% gradient SDS-PAGE gels. 1 μ g of human
879 plasma fibronectin (Sigma-Aldrich, F2006) and 0.1 μ g fibronectin fragment 2 (Sino Biological,
880 10314-H08H) were loaded as control onto the SDS-PAGE gels.

881 b. **Western blot for detecting natural IgM and IgG:** 1 μ g of human plasma fibronectin
882 (Sigma-Aldrich, F2006) and 0.1 μ g fibronectin fragment 2 (FN1.2) (Sino Biological, 10314-
883 H08H) were loaded onto SDS-PAGE gels. Each blot was incubated with 50 μ l of human serum
884 in 5 ml of 3% BSA for overnight at 4 °C. HRP-conjugated anti-human IgG or IgM was used
885 (1:10000 dilution) for detecting the fibronectin bound IgG or IgM.

886 c. **Western blot for detecting IgG against herpesvirus dUTPase:** 5 μ g of recombinant
887 EBV, HSV-1 and HHV-6 dUTPase proteins were loaded onto 10% SDS-PAGE gels. After gel
888 running and transfer onto a nitrocellulose membrane, each membrane was incubated with
889 50 μ l of human serum in 5 ml of 3% BSA for overnight at 4 °C. HRP-conjugated anti-human
890 IgG was used (1:10000 dilution) for detecting the IgG against individual herpesvirus
891 dUTPases. Intensities of appropriate bands were quantified using densitometric analysis. An
892 arbitrary grading system (0, 1, 2 and 3) was used to evaluate amounts of IgG response

893 against respective herpesvirus dUTPases. 0, absent (no IgG response detected); 1, low; 2,
894 moderate; 3, high. Specificity and cross-reactivity of individual herpesvirus IgG against each
895 other was checked.

896

897 **Analysis of mitochondrial membrane potential by TMRE (Tetramethylrhodamine-** 898 **ethylester-perchlorate)**

899 For the analysis of mitochondrial membrane potential HEK293 cells were seeded in 6 well
900 plates. Cells were transfected with plasmids encoding Halo-tagged herpesvirus dUTPase
901 (Supplementary Table 3). After 48 hours cells were trypsinized, washed and counted. For
902 TMRE staining (Sigma-Aldrich, 87917) 2×10^6 cells were washed with PBS and resuspended
903 in a 50 nM TMRE solution in PBS and 137 mM KCl and stained for 10 min at room
904 temperature. Cells were measured by flow cytometer (Attune Flow Cytometers) recording
905 first base level of TMRE fluorescence. Then, half of the cells were treated with 1.5 μ M of
906 Oligomycin (Sigma Aldrich, #04876 in DMSO). Fluorescence was measured at different
907 timepoints of incubation. At the end, 5 μ M FCCP (Carbonyl cyanide-p-trifluoromethoxy-
908 phenylhydrazone, Sigma Aldrich, #C2920) was added to induce mitochondrial depolarization
909 and the changes in fluorescence levels because of loss of membrane potential was
910 measured.

911

912 **Immunoglobulin purification**

913 150 μ l Protein G Sepharose 4 Fast Flow (#17061801, cytiva) was loaded onto Poly-Prep
914 Chromatography Columns (#731-1550, BIO-RAD). After washing the beads with PBS, 500 μ l
915 serum sample was loaded and passed through the column 3 times, which was followed by 3
916 time washing by PBS. Protein G bounded serum IgG was eluted by Glycine pH 2.7 and then
917 neutralised with 1M Tris-HCl pH 8.0. IgG elute was dialyzed against PBS in Slide-A-Lyzer MINI
918 Dialysis Devices (#88404, Thermo Fisher Scientific). IgG concentration was measured by
919 Easy-Titer Human IgG (H+L) Assay Kit (#23310, Thermo Fisher Scientific).

920

921 **Co-immunoprecipitation of His-tagged viral dUTPases**

922 Halo-tagged herpesvirus dUTPase immunoprecipitation (IP) was carried out using standard
923 IP protocol⁵ using ysis buffer (50 mM Hepes, pH 7,5; 150 mM NaCl; 0.5% NP-40; 1 mM NaF;

924 10% Glycerol, 2.5 mM MgCl₂; protease inhibitor cocktail (Roche), 0.5 mM DTT) and wash
925 buffer (50 mM Hepes, pH 7,5; 150 mM NaCl; 1 mM NaF; 10% Glycerol, 2.5 mM MgCl₂;
926 protease inhibitor cocktail (Roche), 0.5 mM DTT).

927

928 **IgG exposure in cell culture**

929 U2-OS or HUVEV-TERT2 cells carrying soluble mitoGFP were seeded on 6-well plates and
930 cultured overnight. Cell culture medium containing 1 µg/ml serum IgG was added to each
931 well, allowing cells to be exposed to serum derived IgG. Cells were collected after 24 h for
932 western blot or immunofluorescence experiments.

933

934 **Fibronectin ELISA**

935 Human fibronectin ELISA was performed with Fibronectin Human ELISA Kit (#BMS2028,
936 Thermo Fisher Scientific) by the manufacturer's protocol.

937

938 **IgM-FN1 and IgG-FN1 ELISA**

939 96 well microplates (Sigma-Aldrich, CLS9018) were coated with 100 ng fibronectin antibody
940 (Santa Cruz, sc-18825) in carbonate coating buffer (Thermo Fisher Scientific, CB01100)
941 overnight at 4°C. For IgG and IgM standard wells, 100 µl 25.60 ~ 0 pg/µl series dilutions of
942 native human IgM protein (Abcam, ab90348) or human IgG isotype control (Thermo Fisher
943 Scientific, 31154) was coated onto the plates in carbonate coating buffer (Thermo Fisher
944 Scientific, CB01100) overnight at 4°C. Plates were then washed 3 times for 5 min by 200 µl
945 1X wash buffer on a plate shaker, which was prepared by diluting 20X TBST (Thermo Fisher
946 Scientific, 28360) in distilled water. 2% BSA (Bovine Serum Albumin) (Sigma-Aldrich, A2153)
947 was dissolved in 1X washing buffer. 300 µl 2% BSA were used to block the plates for 1h at RT
948 and the plates were washed 1 time afterwards. Serum samples from patients and healthy
949 control were diluted 1:100 by 2% BSA. Plates were then incubated with 100 µl diluted serum
950 samples in each well for 1 h at RT on a shaker. Plates were then washed 6 times for 5 min by
951 200 µl 1x washing buffer on a shaker. Goat anti-human IgM-HRP (Thermo Fisher Scientific,
952 31415) and rabbit anti-human IgG-HRP (Sigma-Aldrich, A8792) were used as secondary
953 antibodies for signal detection. Secondary antibodies were diluted 1:10000 in 2% BSA. Plates
954 were incubated with 100 µl of diluted secondary antibody for 1h at RT and then washed 6
955 times for 5 min by 200 µl 1X washing buffer on a plate shaker. HRP signals were developed

956 by incubating the plates with 100 μ l TMB substrate solution (Thermo Fisher Scientific,
957 34029) for 15-30 minutes at RT until desired color was visible and then stopping the reaction
958 by adding 100 μ l stop solution (Thermo Fisher Scientific, SS04). Plates were immediately
959 read by an optical plate reader (Avantor, SpectraMax PLUS384) at 450 nm. The
960 concentration of the samples was calculated by using the standard curves as references.
961 Duplicates were applied for all unknown samples and standard samples.

962

963 **Principles of sandwich ELISA:** Fibronectin antibody (Santa Cruz, sc-18825) was raised against
964 the cell binding domain, which is located within the FN1.2 domain. However, natural IgM
965 against fibronectin only showed binding activity with plasma fibronectin instead of
966 recombinant FN1.2, suggesting that natural IgM against fibronectin and fibronectin antibody
967 (Santa Cruz, sc-18825) have different binding domain. Based on this, we developed our
968 sandwich ELISA for IgM and IgG.

969

970 **Inter- and Intra-assay validation for IgM-FN1 and IgG-FN1:** For inter- and intra-assay
971 accuracy testing, optical density (O.D.) values at 450 nm for standard concentration curves
972 between the range of 0.8 ng/ml to 25.6 ng/ml human native IgM and human IgG controls
973 were generated (Supplementary Table 5a and 5b respectively). Two independent
974 experiments on three different days (Six independent standard curves in total), for both IgM
975 and IgG, were developed and carried out. Intra-assay precision was assessed over these six
976 independent standard concentration curves. Each standard concentration was performed in
977 duplicates. The results showed overall intra-assay coefficients of variation (CV) of 3.45%
978 (range between 0.00% to 14.93%) for IgM and 2.67% (range between 0.00% to 8.62%) for
979 IgG. Inter-assay reproducibility was determined by the overall CV of all mean O.D. values
980 from six independent experiments. The results showed CV of 3.22% (range between 0.02%
981 to 11.47%) for IgM and 3.23% (range between 0.03% to 11.48%) for IgG.

982

983 **Mass spectrometry**

984 A fraction of serum IgG bounded protein G beads from IgG purification was eluted by
985 NuPAGE LDS Sample Buffer (4X) (#NP0007, Thermo Fisher Scientific). The elutes were sent
986 for mass spectrometry.

987

988 **Single-pot, solid-phase-enhanced sample preparation (SP3)**

989 Samples were processed using an adapted SP3 protocol¹⁰. Briefly, 200 µl reconstitution
990 solution was added to each sample prepared in 50 µl NuPAGE LDS sample buffer (Life
991 Technologies). Reduction was performed using 5 mM DTT with subsequent alkylation with
992 20 mM iodoacetamide. 10mM additional DTT was used for quenching. Equal volumes of two
993 types of Sera-Mag Speed Beads (Cytiva, #45152101010250 and #65152105050250) were
994 combined, washed with water and 10²µL of the bead mix were added to each sample. 260
995 µl 100% ethanol was added and samples were incubated for 5 min at 24 °C, 1000 rpm. Beads
996 were captured on a magnetic rack for 2²min, and the supernatant was removed. Beads were
997 washed twice with 200 µl 80% ethanol (Chromasolv, Sigma) and then once with 1000 µl 80%
998 ethanol. Digestion was performed on beads with 0.25 µg Trypsin (Gold, Mass Spectrometry
999 Grade, Promega) and 0.25 µg Lys-C (Wako) in 100 µl 100 mM ammonium bicarbonate at 37
1000 °C overnight. Peptides were desalted using C-18 Stage Tips¹¹. Each Stage Tip was prepared
1001 with three discs of C-18 Empore SPE Discs (3 M) in a 200 µl pipet tip. Peptides were eluted
1002 with 60 % acetonitrile in 0.1 % formic acid, dried in a vacuum concentrator (Eppendorf), and
1003 stored at -20 °C. Peptides were dissolved in 2 % acetonitrile / 0.1 % formic acid prior to
1004 nanoLC-MS/MS analysis.

1005

1006 **NanoLC-MS/MS analysis**

1007 NanoLC-MS/MS analyses were performed on an Orbitrap Fusion (Thermo Scientific)
1008 equipped with a PicoView Ion Source (New Objective) and coupled to an EASY-nLC 1000
1009 (Thermo Scientific). Peptides were loaded on a trapping column (2 cm x 150 µm ID, PepSep)
1010 and separated on a capillary column (30 cm x 150 µm ID, PepSep) both packed with 1.9 µm
1011 C18 ReproSil and separated with a 120-minute linear gradient from 3% to 30% acetonitrile
1012 and 0.1% formic acid and a flow rate of 500 nl/min. Both MS and MS/MS scans were
1013 acquired in the Orbitrap analyzer with a resolution of 60,000 for MS scans and 30,000 for
1014 MS/MS scans. HCD fragmentation with 35 % normalized collision energy was applied. A Top
1015 Speed data-dependent MS/MS method with a fixed cycle time of 3 s was used. Dynamic
1016 exclusion was applied with a repeat count of 1 and an exclusion duration of 90 s; singly
1017 charged precursors were excluded from selection. Minimum signal threshold for precursor
1018 selection was set to 50,000. Predictive AGC was used with AGC a target value of 4x10⁵ for
1019 MS scans and 5x10⁴ for MS/MS scans. EASY-IC was used for internal calibration.

1020

1021 **MS data analysis**

1022 Raw MS data files were analyzed with MaxQuant version 1.6.2.2¹². Database search was
1023 performed with Andromeda, which is integrated in the utilized version of MaxQuant. The
1024 search was performed against the UniProt Human Reference Proteome database (June
1025 2022, UP000005640, 79684 entries), the UniProt HHV-6 Reference Proteome database
1026 (October 2018, UP000009295, 107 entries) and the UniProt Epstein-Barr virus database
1027 (September 2022, UP000272970, 82 entries). For dUTPase co-IP experiment, a small
1028 database containing the sequence of the Halo-Tag (UniProt DHAA_RHORH) and the
1029 dUTPases of interest (UniProt LON6A5, P30007, P03195) was used. Additionally, a database
1030 containing common contaminants was used. The search was performed with tryptic
1031 cleavage specificity with 3 allowed miscleavages. Protein identification was under control of
1032 the false-discovery rate (FDR; <1% FDR on protein and peptide spectrum match (PSM) level).
1033 In addition to MaxQuant default settings, the search was performed against following
1034 variable modifications: Protein N-terminal acetylation, Gln to pyro-Glu formation (N-term.
1035 Gln) and oxidation (Met). Carbamidomethyl (Cys) was set as fixed modification. LFQ
1036 intensities were used for protein quantitation¹³.

1037

1038 For Halo-tag co-IP data analysis, proteins with less than two razor/unique peptides were
1039 removed. Missing LFQ intensities were imputed with values close to the baseline. Data
1040 imputation was performed with values from a standard normal distribution with a mean of
1041 the 5% quantile of the combined log₁₀-transformed LFQ intensities and a standard deviation
1042 of 0.1. For the identification of significantly enriched proteins, boxplot outliers were
1043 identified in intensity bins of at least 300 proteins. Log₂ transformed protein ratios of
1044 sample versus control with values outside a 1.5x (significance 1) or 3x (significance 2)
1045 interquartile range (IQR), respectively, were considered as significantly enriched.

1046

1047 **Antigen Microarray experimental set up**

1048 Microarray studies for IgM against autoantigens were carried out in collaboration with
1049 Creative Biolabs, USA. Frozen serum samples without prior freeze-thaw cycle were used for
1050 the assay. Each serum was digested with DNase I for 30 min at room temperature on a
1051 shaker. For the control, no serum sample was added. Slides carrying antigens against 120

1052 autoantigens (for details of the antigens, please see Supplementary Table 2) were blocked in
1053 100 ml blocking buffer at room temp for 30 min on a shaker. Afterwards slides were washed
1054 twice with PBST each for 5 min. 90 ml PBST was added into each serum sample or control
1055 mix. Diluted samples were added into each well of the slide (100 ml /each) and were
1056 incubate at room temp for 1 hour on a shaker. Slides were washed with PBST 100 ml/well for
1057 5 min on the shaker. Subsequently slides were washed with blocking buffer 100 ml/each well
1058 for 5 min on a shaker and the with PBST 100 ml/each well, 5 min on a shaker. Anti-human
1059 IgM secondary antibody were diluted to 1:1000 in PBST and 100 ml secondary antibody was
1060 added to each well. Slides were incubated at room temp for 1 hour on the shaker, washed
1061 three times with PBST 100 ml/each well, 5 min on the shaker. Slides were then washed twice
1062 each, first with 45 ml PBS in 50 ml tube for 5 min on the shaker and then with 45 ml
1063 nuclease-free water in 50 ml tube for 5 min on the shaker. GenePix 4000B microarray
1064 systems was used to scan the slide. 532 nm channel was used to scan Cy3 fluorescence, and
1065 635 nm channel was used to scan Alexa Fluor-647 fluorescence.

1066

1067 **Microarray data analysis**

1068 Each chip had serially diluted anti-IgM and IgM as positive control to monitor the
1069 experimental process, and PBS was used as a negative control. For the obtained chip image,
1070 LuxScan 3.0 software was used to read the original data. Statistical tests were then carried
1071 out on the chip background, the signal intensity of the positive and negative control sites.
1072 The results showed that the Ig control signal value was higher, and the uniformity was good
1073 in different samples. In addition, the value of PBS anti-Ig control and background signal value
1074 were all low, which met the quality control requirements. The chip of the test sample was
1075 scanned with LuxScan 10K-B scanner. Autoantigen microarray chip/ Pathogen-associated
1076 antigen microarray chip had 256 points in total. After removal of the 8 anti-IgM and 8 Ig
1077 control points, 240 data points were finally obtained. Each protein on the chip was present
1078 as two technical repetitions, representing 120 autoantigens. The chip is read by LuxScan 3.0
1079 software to obtain the original data, including foreground signal (F Median), background
1080 signal (B Median) and so on. Foreground Median, Background Median columns were
1081 extracted from the .LSR file. Fluorescence intensity value of each site was calculated by the
1082 formula: Net Fluorescence Intensity (NFI) Value = (Foreground Median - Background
1083 Median); SNR = (Foreground Median - Background Median) / SD(Background). SNR was used

1084 to filter unreasonable data. The net fluorescence value was set as $SNR < 0.05$ and SNR to
1085 0.001. The net fluorescence value was calculated after subtracting the blank control PBS
1086 $NFI_{No\ PBS}$. The NFI and SNR of the following unreasonable situations was set to 0.001.
1087 $NFI < 20$ and $SNR > 5$; $SNR < 0.05$ and $NFI > 20$; $NFI < 0.05$. RLM Normalization was used to
1088 normalize the NFI and calculate the effect values of different blocks and slides. For the
1089 microarray data clustering and multivariate analysis, first log transformation was carried out
1090 and then 'pheatmap' was used using R package with Ward.D2 clustering to make the cluster
1091 analysis.

1092

1093 **Machine learning and Multivariate analysis of autoantigen IgM microarray data**

1094 Multivariate analysis of patient clusters based on distance metrics derived from IgM
1095 antibody levels against for a panel of autoantigens. Columns with zero variation (constant
1096 values) were removed. Log-transformed scaled data showing relative differences between
1097 patients was used because the data in its raw form had different orders of magnitude,
1098 making analysis and comparison difficult. The analysis was performed using the R package
1099 "pheatmap" using Ward.D2 clustering method and Euclidean distances.

1100

1101 A RandomForest classifier using the R package randomForest was fit predicting ME/CFS as
1102 an outcome was performed on two types of data - raw data and log scaled data. The
1103 purpose of this fit was a rapid screen for variables for further analysis. The Variable
1104 Importance Plot for the fits were plotted. The top 10 candidates from the Log Variable
1105 Importance Plots were selected for Principal Component Analysis (PCA), a statistical
1106 methodology for dimension reduction. PCA was was performed using the R package stats
1107 (prcomp) and FactoMineR.

1108

1109 **Statistical testing of herpesvirus dUTPase antibody**

1110 As a part of the Likert Analysis, the following steps were performed: Counts and percentage
1111 of totals were generated in R using dplyr package. The above results were grouped into
1112 relevant sets (EBV, HSV-1, HHV-6, Healthy, ME/CFS, Covid-19 PCR positive but no long COVID
1113 (No LC), Mild LC, Severe LC). Likert charts were generated from the above groupings.

1114

1115 Non-parametric analysis was performed because the groups were of different sizes. The R
1116 package “rcompanion” was used because it has the higher order non-parametric
1117 ScheirerRayHare Test. Kruskal Wallis and its associated higher order test ScheirerRayHare
1118 Test were performed because two factors (Antibody State, i.e., 0, 1, 2, 3 and virus state, i.e.,
1119 EBV, HSV-1, HHV-6) are changing simultaneously and it would be useful to know which
1120 factor was statistically significant. For several tests, it appeared that Antibody State was
1121 significant.

1122

1123 **Other statistics**

1124 Kernel density plot showing the bivariate serum FN1 distributions among healthy controls
1125 and ME/CFS patients was performed using the Python package package Seaborn
1126 (*Seaborn.kdeplot*). All other statistical calculations were performed using GraphPad Prism
1127 9.0. Error bars displayed on graphs represent the means \pm SD of three or more independent
1128 replicates of an experiment. Statistical significance was calculated separately for each
1129 experiment and are described within individual figure legends. For image analysis, three or
1130 more biological replicates per sample-condition were used to generate the represented
1131 data. The results were considered significant at $P \leq 0.05$.

1132

1133 **Reporting summary**

1134 Further information on research design is available in the Nature Research Reporting
1135 Summary linked to this paper.

1136

1137 **Data and Materials availability:**

1138 Further information and requests for resources and reagents should be directed to Bhupesh
1139 K Prusty (bhupesh.prusty@uni-wuerzburg.de). The mass spectrometry proteomics data for
1140 the serum immunoglobulin proteome study have been deposited to the ProteomeXchange
1141 Consortium via the PRIDE partner repository with the dataset identifier PXD041945 and the
1142 same for HEK293 dUTPase co-IP proteome study with the dataset identifier PXD041942. All
1143 the experimental data are deposited to Mendley (doi: 10.17632/4xkft5g9r5.1).

1144

1145 **References for Methods:**

1146 1 Bahmer, T. *et al.* Severity, predictors and clinical correlates of Post-COVID syndrome
1147 (PCS) in Germany: A prospective, multi-centre, population-based cohort study.
1148 *EClinicalMedicine* **51**, 101549, doi:10.1016/j.eclinm.2022.101549 (2022).
1149 2 Horn, A. *et al.* Long-term health sequelae and quality of life at least 6 months after
1150 infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the
1151 NAPKON population-based cohort platform (POP). *Infection* **49**, 1277-1287,
1152 doi:10.1007/s15010-021-01707-5 (2021).
1153 3 Wagner, M. *et al.* Characteristics and Course of Heart Failure Stages A-B and
1154 Determinants of Progression - design and rationale of the STAAB cohort study. *Eur J*
1155 *Prev Cardiol* **24**, 468-479, doi:10.1177/2047487316680693 (2017).
1156 4 Morbach, C. *et al.* Prevalence and determinants of the precursor stages of heart
1157 failure: results from the population-based STAAB cohort study. *Eur J Prev Cardiol* **28**,
1158 924-934, doi:10.1177/2047487320922636 (2021).
1159 5 Hennig, T. *et al.* Selective inhibition of miRNA processing by a herpesvirus-encoded
1160 miRNA. *Nature* **605**, 539-544, doi:10.1038/s41586-022-04667-4 (2022).
1161 6 Chowdhury, S. R. *et al.* Chlamydia preserves the mitochondrial network necessary for
1162 replication via microRNA-dependent inhibition of fission. *J Cell Biol* **216**, 1071-1089,
1163 doi:10.1083/jcb.201608063 (2017).
1164 7 Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nat*
1165 *Methods* **9**, 676-682, doi:10.1038/nmeth.2019 (2012).
1166 8 Prusty, B. K., Chowdhury, S. R., Gulve, N. & Rudel, T. Peptidase Inhibitor 15 (PI15)
1167 Regulates Chlamydial CPAF Activity. *Front Cell Infect Microbiol* **8**, 183,
1168 doi:10.3389/fcimb.2018.00183 (2018).
1169 9 Gulve, N. *et al.* Anti-herpesviral effects of a novel broad range anti-microbial
1170 quaternary ammonium silane, K21. *Antiviral Res* **131**, 166-173,
1171 doi:10.1016/j.antiviral.2016.05.004 (2016).
1172 10 Hughes, C. S. *et al.* Single-pot, solid-phase-enhanced sample preparation for
1173 proteomics experiments. *Nat Protoc* **14**, 68-85, doi:10.1038/s41596-018-0082-x
1174 (2019).
1175 11 Rappsilber, J., Ishihama, Y. & Mann, M. Stop and go extraction tips for matrix-assisted
1176 laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in
1177 proteomics. *Anal Chem* **75**, 663-670, doi:10.1021/ac026117i (2003).
1178 12 Cox, J. & Mann, M. MaxQuant enables high peptide identification rates,
1179 individualized p.p.b.-range mass accuracies and proteome-wide protein
1180 quantification. *Nat Biotechnol* **26**, 1367-1372, doi:10.1038/nbt.1511 (2008).
1181 13 Cox, J. *et al.* Accurate proteome-wide label-free quantification by delayed
1182 normalization and maximal peptide ratio extraction, termed MaxLFQ. *Mol Cell*
1183 *Proteomics* **13**, 2513-2526, doi:10.1074/mcp.M113.031591 (2014).

1184

1185

1186

1187 **Extended Figure legends:**

1188

1189 **Extended Fig. 1: Herpesvirus reactivation in healthy population, ME/CFS, long COVID**
1190 **patients.**

1191 **a.** Demography of distribution of patients according to the age and gender.

1192 **b.** Likert chart showing percentage of positivity for antibodies against EBV, HSV-1 and HHV-6
1193 dUTPase within healthy controls (HC), ME/CFS, Covid-19 PCR positive but without long
1194 COVID (No LC), mild LC and severe LC patients. Kruskal Wallis (and its higher order
1195 equivalent, ScheirerRayHare Test) rank sum test for antibody state. HC, *P = 0.019; ME/CFS,
1196 *P = 0.021.

1197 Different amounts IgG levels in patient serum was arbitrarily divided into 4 groups (0,
1198 absent; 1, low; 2, moderate; 3, high).

1199

1200 **Extended Fig. 2: Role of viral dUTPase proteins in mitochondrial dysfunction.**

1201 **a.** Confocal images showing hyperpolarization of mitochondria in U2-OS cells under transient
1202 expression of HSV-1, HHV-6 and EBV dUTPases. Mock vector was used as a control.

1203 **b.** Average mitochondrial surface area was compared between mock vector and EBV
1204 dUTPase transfected U2-OS cells. Data from three independent biological replicates. n=3.
1205 Unpaired two tailed non-parametric t-test. *P = 0.0278.

1206 **c.** Immunoblot analysis shows no major changes in dynamin related protein 1 (Drp1), p53,
1207 mitofusin1 (Mfn2), mitoguardin1 (Miga1) protein levels in presence of herpesvirus
1208 dUTPases. GAPDH staining was used as a loading control.

1209 **d.** TMRE dye was used to study mitochondrial membrane potential and OXPHOS in HEK293
1210 cells. Cells were transiently transfected with HHV-6, HSV-1 dUTPases or a mock vector for 48

1211 **h.** Non-transfected cells are also used as a control. Trypsinized cells were stained with TMRE

1212 dye and were used for flow cytometry. Oligomycin was used to inhibit ATP synthase. Data
1213 from 3 independent experiments. n=3.

1214 **e.** Data from above experiment was used to compare hyperpolarization status of
1215 mitochondria between mock transfected and EBV dUTPase transfected cells. Data from 3
1216 independent experiments. n=3.

1217 **f.** Confocal images showing fragmentation of mitochondria in U2-OS cells in presence of
1218 recombinant EBV dUTPases. Same amounts of heat inactivated recombinant protein was
1219 used as a control. Average mitochondrial surface area was compared between control and
1220 recombinant EBV dUTPase exposed U2-OS cells. Data from four independent biological
1221 replicates. n=4. Unpaired two tailed non-parametric t-test. **P = 0.0032.

1222 **g.** Immunoblot analysis shows upregulation of dynamin related protein 1 (Drp1) levels in U2-
1223 OS cells exposed to recombinant EBV dUTPase for 24 h in a dose dependent manner. GAPDH
1224 staining was used as a loading control. Drp1 levels are quantified from three independent
1225 biological replicates and are shown in the form of a scatter plot. n=3. Unpaired two tailed
1226 non-parametric t-test. 0 vs 2 μ g, *P = 0.0229; 0 vs 5 μ g, *P = 0.0360; 0 vs 10 μ g, *P = 0.0201.

1227 **h.** TMRE dye was used to study mitochondrial membrane potential and OXPHOS in HEK293
1228 cells exposed to recombinant EBV dUTPase. Trypsinized cells were stained with TMRE dye
1229 and were used for flow cytometry. Oligomycin was used to inhibit ATP synthase. Data from 3
1230 independent experiments. n=3.

1231 **i.** Coomassie dye stained polyacrylamide gel with input and immunoprecipitated samples
1232 shows efficient pull down of Halo-tagged herpesvirus dUTPases. Potential protein bands co-
1233 immunoprecipitated along with EBV and HSV-1 dUTPase protein is indicated.

1234 **j.** Normalized log₂ ratio of LFQ (label-free quantitation) intensities of proteins. Fold change
1235 of proteins in EBV vs Mock was plotted against the same in HHV-6 vs Mock to highlight
1236 proteins that were specifically enriched in EBV dUTPase expressing co-IP.

1237 **k.** Normalized log₂ ratio of LFQ (label-free quantitation) intensities of proteins. Fold change
1238 of proteins in HSV-1 vs Mock was plotted against the same in HHV-6 vs Mock to highlight
1239 proteins that were specifically enriched in HSV-1 dUTPase expressing co-IP.

1240 Circles indicate identified cellular proteins; circle size correlates with the number of peptides
1241 used for quantification. Significantly enriched proteins that are potential interaction partners
1242 of EBV (g) and HSV-1 (h) dUTPases are displayed in red.

1243 **l.** Immunoblot analysis to validate potential herpesvirus dUTPase interacting partners
1244 identified from co-IP.

1245

1246 **Extended Fig. 3: Immune modulations in ME/CFS.**

1247 **a.** Immunoblot analysis shows validation of enrichment IgG against EBV dUTPase within
1248 purified IgG fractions. Recombinant dUTPase proteins are used as a bait. Left panel shows
1249 specific detection of EBV dUTPase using an antibody raised against it. Middle panel shows
1250 lack of specific signal against EBV dUTPase using a patient serum negative for EBV. Right
1251 panel confirms the absence of the specific signal against EBV dUTPase within the purified
1252 IgG. GAPDH staining was used as a loading control.

1253 **b.** Immunoblot analysis shows positive validation of enrichment IgG against EBV dUTPase
1254 within purified IgG fractions. Recombinant dUTPase proteins are used as a bait. Left panel
1255 shows specific detection of EBV dUTPase using an antibody raised against it. Middle panel
1256 shows specific signal against EBV dUTPases using a EBV positive patient serum. Right panel

1257 confirms the presence of the specific signal against EBV dUTPase within the purified IgG.

1258 Desired band is indicated with an arrow. GAPDH staining was used as a loading control.

1259 **c.** A heat map of proteins identified by mass spectrometry within the purified
1260 immunoglobulin complexes. Each row represents a specific protein, and each column
1261 represents a specific patient sample. The lower panel of the heat map from upper panel is
1262 enlarged in the lower panel along with the protein names.

1263 **d.** Log₁₀ values of normalized LFQ intensities of three altered proteins (serotrasferrin,
1264 alpha2 microglobulin and fibronectin) comparing healthy controls (n=12) with ME/CFS
1265 patients (n=15).

1266

1267 **Extended Fig. 4: Autoimmune signatures in ME/CFS.**

1268 **a.** The Variables Factor map (Biplot) for the Principal Components (for patients and healthy
1269 Controls combined data) shows the projection of the top 10 Autoantigen variables projected
1270 onto the plane spanned by the first two Principal Components.

1271 **b.** Biplot of PCA analysis showing variation condensed to key dimensions (dim reduction) for
1272 the data set shown in Fig. 2e-f.

1273

1274 **Extended Fig. 5: Circulating fibronectin in ME/CFS.**

1275 **a.** Immunoblot analysis shows overall increase in both plasma fibronectin (pFN1) and
1276 cellular fibronectin (cFN1) in ME/CFS patients. Equal amounts of serum proteins from 5
1277 ME/CFS patients with higher serum fibronectin levels were run in parallel with the same
1278 from 5 healthy controls. Purified pFN1, recombinant fibronectin isoform FN1.2 and HUVEC
1279 cell lysate expressing only cellular fibronectin were used as positive controls. Two different

1280 antibodies raised against Extra domain A (EDA) domain and CBD domain of fibronectin was
1281 used to differentiate pFN1 from cFN1 as pFN1 lacks EDA domain.

1282 **b.** Distribution of circulating FN1 concentrations in different groups of patients separated by
1283 gender. Two-tailed parametric t-test. Healthy control (HC) male vs female, $^{**}P = 0.0014$; No
1284 LC male vs female, $^{*}P = 0.0204$; severe LC male vs female, $^{*}P = 0.0347$.

1285 **c.** Comparison of gender-specific circulating FN1 concentrations (\log_2 values) among
1286 different patient groups. Two-tailed parametric t-test. Healthy control (HC) male vs ME/CFS
1287 male, $^{***}P = 0.0001$; HC male vs mild LC male, $^{*}P = 0.012$; HC female vs no LC female, $^{*}P =$
1288 0.0193 ; HC female vs mild LC female, $^{***}P = 0.0006$; HC female vs severe LC female, $^{**}P =$
1289 0.0016 .

1290 **d.** IgM antibody levels against fibronectin (FN1) in ME/CFS patients and healthy controls in
1291 the form of a violin plot. IgM levels were determined from microarray studies where each
1292 antigen was tested twice separately. Normalized values against signal to noise ratio and net
1293 fluorescence intensity is used.

1294 **e.** Immunoblot analysis comparing the various species of circulating fibronectin (FN1)
1295 proteins in healthy controls and ME/CFS patient sera. Recombinant FN1.2 (recFN1.2) protein
1296 lacking extra domain-A (EDA domain) and HEK293 cell lysate serves as control. Three
1297 different antibodies detecting specific protein domains (EDA domain, CBD (cell binding
1298 domain) and cellular FN (cFN)) of FN1 was used against the same samples to compare the
1299 different species of proteins in the sera.

1300

1301 **Extended Fig. 6: IgM-PC and IgM-MDA distributions among different groups of patients.**

1302 **a.** Distribution of serum IgM-PC concentrations in different groups of patients separated by
1303 gender.

1304 **b.** Distribution of serum IgM-MDA concentrations in different groups of patients separated
1305 by gender.

1306

1307 **Extended Fig. 7: IgM-FN1 and IgG-FN1 distributions among different groups of patients.**

1308 **a.** Distribution of serum IgM-FN1 concentrations in different groups of patients separated by
1309 gender. Two-tailed parametric t-test. ME/CFS male vs female, *P = 0.0398.

1310 **b.** Distribution of serum IgG-FN1 concentrations in different groups of patients separated by
1311 gender.

1312 **c.** Comparison of gender-specific IgM-FN1 concentrations (log₂ values) among different
1313 patient groups. Two-tailed parametric t-test. Healthy control (HC) male vs No LC male, **P =
1314 0.003; HC male vs mild LC male, **P = 0.0018; HC male vs severe LC male, ***P = 0.0007; HC
1315 female vs no LC female, HC female vs mild LC female, HC female vs severe LC female, ****P
1316 < 0.0001.

1317

1318 **Extended Fig. 8: Graphical abstract summarizing potential overlap between ME/CFS and**
1319 **long COVID pathogenesis.**

1320 Both ME/CFS and long COVID possibly originates as a post viral illness. SARS-CoV-2 infection
1321 is the major infection behind long COVID. However, heightened reactivation of herpesviruses
1322 like HSV-1 and EBV can potentially play a role in development of ME/CFS. Similar increase in
1323 herpesvirus reactivations including those of HSV-1, HHV-6 and EBV are also observed in
1324 ME/CFS. Virus-induced direct changes in cellular physiology are expected to be the major
1325 driver for the disease development. Subsequently, chronic tissue inflammation could lead to
1326 changes in secondary tissue homeostasis where increase in circulating fibronectin levels can
1327 play a key role in TLR2/TLR4-mediated innate immune response, cytokine production,

1328 Platelet activation, mast cell activation and alterations in clot homeostasis. Major cellular
1329 alterations within primary and secondary hematopoietic tissues might lead to substantial
1330 decrease in natural IgM production, which subsequently drive the autoimmune feature of
1331 both ME/CFS and long COVID. Changed autoimmune signature in the form of autoantibodies
1332 could then cause mitochondrial dysfunction, endothelial cell damage initiating a vicious
1333 cycle of events that can lead to severe forms of both ME/CFS and long COVID.

1334

1335

1336



1337

1338


1339

1340





Extended Fig. 1





Extended Fig. 2





Extended Fig. 3






Extended Fig. 4




Extended Fig. 6



Extended Fig. 7



Extended Fig. 8



medRxiv preprint doi: <https://doi.org/10.1101/2023.06.23.23291827>; this version posted June 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.


Fig. 1


Fig. 2


Fig. 3

Fig. 4

